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Abstract 

Marine environment is prolific in organisms with unique properties. Seas and 
oceans contain a wide diversity of species with biologically active metabolites 
that represent a valuable source with great potential for the development of 
novel therapeutic agents. This dissertation is focused on the biological study 
of synthetic compounds based on marine scaffolds as well as on marine 
natural product extracts originating from the Aegean Sea. Furthermore, it 
offers an introduction on the importance of marine natural products in the 
search of new bioactive compounds, the use of natural products as scaffolds 
for the synthesis of new drugs, and a general overview on bioactivity 
screening and the current status of marine-derived bioactive compounds as 
therapeutic agents. 
 
The potential of oroidin and clathrodin as parent structures for synthesis of 
novel compounds was explored. Antimicrobial and antiproliferative studies 
were conducted and it was concluded that 4-phenyl-2-aminoimidazoles 6g(I) 
and 6h(I) showed the best antimicrobial effect against Gram-positive bacteria 
(Enterococcus faecalis and Staphylococcus aureus), while compound 6j(I) 
showed the most interesting IC50 in antiproliferative studies. Compound 7(II), a 
synthetic derivative of 2-aminobenzothiazole, showed IC50 of 16 μM and 71 
μM against a cancer cell line and a normal cell line, respectively. The 
selectivity index showed selectivity towards cancerous cells. In addition, 
okadaic acid was used as inspiration for the synthesis of crown ether acyl 
compounds. Compound (1,4,7,10,13,16-hexaoxacyclooctadecan-2-yl)methyl 
3-(pyren-1-yl)propanoate) 1o(III) was found to be the most active in 
antimicrobial studies against Gram-positive Staphylococcus aureus with a 
MIC50 of 7.2 μM. 
 
The importance of bioprospecting the rich marine biodiversity in the Aegean 
Sea was also studied in this thesis. Biological activities of extracts from 
cyanobacteria, micro- and macroalgae were evaluated, and microalgae 

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extracts (Amphora cf capitellata and Nitzschia communis) showed the most 
interesting antimicrobial results against Staphylococcus aureus and fungus 
Candida albicans. 
 
The results of the biological studies conducted in this thesis demonstrated 
antimicrobial and antiproliferative activity of several marine natural products 
and their synthetic derivatives. Further studies and structural optimization 
should be done to fully explore their potential for the development of 
therapeutic agents. 
  
 
 
 
 
 


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Resumo 
 
O ambiente marinho é promissor na variedade de organismos com 
propriedades únicas. Dos mares e oceanos, existe uma diversidade imensa 
de metabólitos bioactivos que representam uma fonte de enorme valor e com 
grante potencial para o desenvolvimento de novos agentes terapêuticos. Esta 
tese mostra o estudo biológico de compostos sintéticos com base em 
“scaffolds” marinhos e extractos do Mar Egeu. Além disso, esta tese oferece 
uma introdução sobre a importância de produtos naturais marinhos e a 
procura de novos compostos bioactivos, no uso de produtos naturais como 
“scaffolds” para a síntese de novos fármacos e uma visão geral sobre 
avaliação da capacidade biológica de compostos marinhos  e o status de 
compostos bioactivos como agentes terapêuticos 
 
O potential do composto clathrodin como modelo para a síntese de novos 
compostos foi explorado. Estudos antimicrobianos e antiproliferativos foram 
realizados e concluiu-se que 4-phenyl-2-aminoimidazoles 6g(I) e 6h(I) teve os 
melhores resultados antimicrobianos quando testados contra bactérias Gram-
positivas (Enterococcus faecalis and Staphylococcus aureus) enquanto que o 
composto 6j(I) mostrou o IC50 mais interessante nos estudos 
antiproliferativos. O composto 7(II), um derivado sintético de 2-
aminobenzotiazole mostrou IC50 de 16 μM e 71 μM quando testado contra 
uma linha celular cancerígena e uma linha celular não-cancerígena, 
respectivamente. O índice de selectividade mostrou uma selecção para 
células cancerígenas. O ácido ocadáico foi usado como inspiração para a 
síntese de compostos macrocíclicos. Composto (1,4,7,10,13,16-
hexaoxacyclooctadecan-2-yl)methyl 3-(pyren-1-yl)propanoate) 1o(III) foi o 
mais activo em estudos antimicrobianos quando testado contra a bactéria 
Gram-positiva Staphylococcus aureus, com MIC50 igual a 7.2 μM. 
 
A importância de bioprospecção da enorme biodiversidade marinha no Mar 
Egeu, foi também estudado nesta tese. Estudos biológicos foram feitos em 

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extratos de cyanobacteria, micro- e macroalgas e as microalgas marinhas 
(Amphora cf capitellata e Nitzschia communis) mostraram a melhor actividade 
antimicrobial, quando testados contra a bacteria Staphylococcus aureus e o 
fungo Candida albicans.  
 
Os resultados preliminares de estudos biológicos em compostos marinhos, 
presentes nesta tese, mostraram o potencial destes em terapias 
antimicrobianas e anticancerígenas. Num futuro próximo, uma optimização na 
estrutura química destes compostos poderá ser realizada, para explorar todo 
o potencial como agentes terapêuticos. 
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1. Introduction 

Yuri Gagarin once said, “The Earth is blue. How wonderful. It is amazing.” 
These were the words of the first human astronaut to travel into space and 
orbit our planet. Approximately three quarters, i.e. 77%, of planet Earth is 
occupied by water and because of that, some scientists believe that the word 
“Earth” should have been replaced by “Water”. As a consequence of the 
amount of water on the planet, the marine biodiversity is enormous ‒ from 
shallow coastal waters to deep oceans ‒ and is being considered a promising 
source of unique secondary metabolites for research and drug discovery [1]. 
Secondary metabolites – compounds not directly involved in the normal 
growth, development or reproduction [2], and with a molecular weight (MW) 
below 2 kDa – are normally produced as an answer to ecological pressures, 
such as competition for space, deterrence of predation, reproduction, among 
others [3]. Bergmann et al. reported the first discovery of a biologically active 
marine natural compound in the late 1950s – arabino and ribo-pentosyol 
nucleosides extracted from Cryptotethia crypta sponge, which was the first 
demonstration that naturally occurring nucleosides could contain sugars other 
than ribose and desoxyribose [4]–[6]. Chemical synthesis allowed the 
development of two derivatives, cytarabine and vidarabine, nucleosides with 
significant anticancer and antiviral activities [7]. However, only after the 
discovery of several prostaglandins, isolated from octocoral Plexaura 
homomalla [8], interest in marine-related research has increased.  
 
Due to their broad panel of biological activities, such as their antibacterial, 
antifungal, anticancer, antiviral, anti-inflammatory, anticoagulant, 
antiprotozoal, antituberculosis, antidiabetic, antimalarial and antioxidant 
effects [9]–[12], marine natural products (MNPs) are remarkably interesting, 
high-value ingredients for applications not only in the pharmaceutical industry, 
but also in the cosmetic, nutraceutical and agrochemical industries [13]–[15]. 
The following review provides a comprehensive overview of the importance of 
marine compounds with a focus on the pharmaceutical field. 

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2. Review of literature 
2.1. Sources of MNPs: overview of the marine-derived sources used in 
the search of new bioactive compounds  

The extraordinary biological, biochemical and biosynthetic potential of marine 
organisms show that oceans and seas are promising hotspots in the research 
of secondary metabolites [9], [16]–[21]. Comparing the taxonomic levels, 76 
phyla are recognized by the “Catalogue of Life” (online database of the 
world’s known species [22]), of which 60 include marine representatives, while 
40 phyla are represented by terrestrial ones. Such a high number of 
representatives show great biological diversity, corroborating the fact that 
oceans and seas are the greatest source for the discovery of new therapeutic 
agents [23]. 
 
From mid-1980s until 2012, there has been an outstanding increase in 
discovered MNPs, mainly due to several advances in technology, and more 
than 22 000 compounds have been isolated from marine organisms (Figure 
1). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 shows data on marine-derived sources used in the discovery of new 
bioactive compounds from 2010 to 2013. More than 30% of new bioactive 
Figure 1: Trend in the number of marine natural products from 1985 to 
2012 [178]. 

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compounds reported from marine sources are derived from microorganisms 
such as cyanobacteria and microalgae. 
 
Microalgae, one of the first photosynthetic microorganisms have been 
highlighted as the new source of marine bioactive compounds due to their 
interesting biological activities [24]. Their enormous biodiversity results from 
the capability to adapt to different environments, some of them extreme. To 
tolerate extreme adverse environments, microalgae develop defense 
strategies, resulting in a high diversity of compounds from different metabolic 
pathways. As cyanobacteria, some species of microalgae can produce value-
added compounds such as antioxidants, polyunsaturated fatty acids (PUFAs), 
polysaccharides and sterols [25]. Other microalgae also produce high 
quantities of hydrocarbons – convertible into biodiesel or hydrogen used as 
alternative energy sources. In structure and function, microalgae can be 
prokaryotic or eukaryotic: the prokaryotic ones belong to the Cyanophyta 
Microorganisms; 
38%
Sponges; 20%
Algae; 14%
Others; 16%
Coelenterates; 
4%
Mollusks; 5% Echinoderms; 
1%
Bryozoans; 2%
Figure 2: Overview of marine natural products in the discovery of novel bioactive
compounds, from 2010 to 2013 (Adapted from: [179]). 
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group (cyanobacteria)  ; the eukaryotic ones are included mainly in 
Bacilariophyceae (diatoms), Dinophyceae (dinoflagellates), Prymnesiophycae 
(coccolithophores), Cryptophyceae (cryptomonas), Prasinophyceae and 
Chlorophyceae. It is estimated that until now, around 30 000 microalgae have 
been studied and analyzed [26]. Chlorella sp. are eukaryotic green unicellular 
microalgae from the Chlorophyta group that has been extensively studied due 
to antitumoral, antibacterial, anticoagulant and antioxidant effects [27], [28]. 
These microalgae, reported to possess antimicrobial activity originally in 1945 
[29], are rich in chlorophyll, polysaccharides, vitamins, minerals and essential 
amino acids [30]. Other species widely studied due to their tolerance of 
extreme habitat conditions and physiological aspects are green unicellular 
halotolerant microalgae that belong to the Chlorophyceae group: Dunaliella 
sp. These microalgae contain carotenoids, glycerol, lipids, enzymes and 
vitamins [31], and are known for their antioxidant, antibacterial and analgesic 
properties [32]. 
 
Cyanobacteria (or blue-green algae) are prokaryotic organisms and studies 
confirm that these organisms have existed approximately for 3.5 billion years 
[33], [34]. They are considered one of the main organisms responsible for the 
creation of the current Earth’s atmosphere [35]. All cyanobacteria are 
photoautotrophs, but there are some groups that can show also heterotrophic 
metabolism, described as mixotrophics. Endowed with the capacity to adapt 
to a wide range of environmental conditions, cyanobacteria colonize 
terrestrial, aquatic and extreme ecosystems. However, the majority of these 
organisms live in water. They have been studied broadly due to their capacity 
of producing bioactive compounds, such as toxins (microcystins), 
siderophores and antibiotics. The use of cyanobacteria in medicine and 
pharmacology dates back to 1500 B.C., when strains of Nostoc were used to 
treat gout, fistula and several forms of cancer [36]. Between 1950 and 1970, 
studies on prospecting, isolation and characterization of cyanobacteria started 
to be carried out regularly [37], [38]. After 1990, research on these 

 In some studies, cyanobacteria are considered members of the Bacteria domain.  

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prokaryotics received more emphasis and the pioneering work led by Richard 
Moore and William Gerwick showed the value of cyanobacteria for biomedical 
research [20]. The interest in studying compounds produced by marine 
cyanobacteria is also related to the fact that some of the isolated compounds 
show enormous structural variety, making them interesting as scaffolds for the 
synthesis of new drugs. Compounds derived from filamentous genera such as 
Lyngbya, Leptolyngbya and Symploca have shown anticancer activity [39]–
[41]. In a review conducted by Tan [42], in which 128 compounds isolated 
from marine cyanobacteria were studied, more than 35% of the compounds 
showed activity in tumoral cell lines and 10% of compounds exhibited activity 
in normal cell lines (non-tumoral). Some of the compounds showed 
antimicrobial and anti-inflammatory activities. Table 1 shows examples of 
bioactive compounds from marine cyanobacteria, their chemical class, 
species (source) and biological activity. 
 
Table 1: Bioactive compounds from cyanobacteria.
Compound Chemical class Source 
Biological 
activity 
Reference 
Ambiguine Alkaloid Fischerella ambigua Antimicrobial [43], [44] 
Aulosirazole Aromatic Aulosira fertilissima Anticancer [45] 
Cryptophycin Lipopeptide Nostoc sp. Cytotoxic 46], [47] 
Didemnin Lipopeptide 
Synechocystis 
trididemni 
Anticancer, 
antiviral 
[48] 
Dolastatin Lipopeptide 
Lyngbya sp. 
Symploca sp. 
Anticancer [49] 
Hapalindole Alkaloid Fischerella sp. 
Cytotoxic, 
antibacterial 
[44] 
Hassallidin 
Nonribosomal peptide 
synthetase (NRPS) 
Anabaena sp. Antifungal [50] 
 
Macroalgae, macroscopic and multicellular seaweeds, existing in abundance, 
are potential renewable resources that have been explored as novel and 
sustainable sources of compounds for pharmaceutical and nutraceutical 
applications. These marine algae can be classified according to the presence 

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of specific pigments into three main groups: Chlorophyta (green algae), 
Phaeophyta (brown algae) and Rhodophyta (red algae). The color of green 
algae is caused by the presence of green pigments called chlorophylls (a and 
b). The presence of fucoxanthin, chlorophyll (a and c) gives Phaeophyta a 
greenish brown color. The red color of Rhodophyta is attributed to the 
presence of phycobilins (phycoerythrin and phycocyanin). Several species of 
macroalgae have the capacity to produce a diverse array of secondary 
metabolites of potential medicinal values as antimicrobial [51]–[53] and 
antiproliferative agents [54]. Vairappan et al. showed antibacterial activities of 
eight halogenated compounds, isolated from five species of red algae 
Laurencia sp., against a range of Gram-positive bacteria, including antibiotic-
resistant bacteria [55].  
From the red alga Odonthalia corymbifera, bromophenol compounds have 
been isolated and synthesized, and antimicrobial activity tested against Gram-
positive and Gram-negative bacteria and fungi [56]. The most active isolated 
compound was 2,2’,3,3’-tetrabromo-4,4’,5,5’-tetrahydroxydiphenylmethane, 
displaying activity against Candida albicans, Aspergillus fumigatus and 
Trichophyton sp. Two synthetic analogs from the same alga showed potent 
antibacterial effect against Staphylococcus aureus, Bacillus subtilis, Proteus 
vulgaris, Micrococcus luteus and Salmonella typhimurium. 
The antibacterial activity of two species of brown algae Ecklonia (Ecklonia 
kurome and Ecklonia stolonifera) have been evaluated against S. aureus, 
Escherichia coli, Pseudomonas aeruginosa and Bacillus cereus [57] and 
significant activity was observed against all bacteria except Gram-negative E. 
coli.  
 
Another important marine resource are sponges (Porifera) – sessile aquatic 
animals that live in rivers or deep oceanic waters. These organisms constitute 
a mark in the evolutionary history of planet Earth, being one of the oldest 
existing lineages of metazoans. It is estimated that sponges appeared in 
Neoproterozoic Era more than 635 million years ago [58]. Recent studies 
indicate that Porifera played an important role in the oxygenation of the 

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oceans [59]. Since sponges are benthic (fixed to the seabed during adult life) 
and with a simple morphology, they were able to develop, among others, an 
adaptive chemical strategy as a way of defense and competition. Many of the 
secondary metabolites from sponges present novel chemical structures, 
showing interesting biological activities [60]–[62]. Antimicrobial studies of 
secondary metabolites isolated from Lotrochota purpurea – i.e. halogenated 
alkaloids purpuroines A-J – have been reported to demonstrate inhibitory 
activity against fungi and bacteria [63]. The extract of an Indonesian marine 
sponge, Haliclona sp., have been shown to display potential cytotoxic activity 
against human solid cancer cell lines [MCF-7 (breast), LNCap (prostate), 
Caco-2 (colon) and HCT-15 (colon) cells] [64]. Among approved MNPs 
derived from sponges (Sub-chapter 2.5.1), there are some that have recently 
entered into clinical trials for cancer treatment, such as the synthetic tripeptide 
hemiasterlin, first identified from the marine sponge Cymbastela sp. [65]. 
 
2.1.1. Main classes of marine bioactive compounds 

The following sub-chapters describe the most relevant chemical classes of 
marine natural compounds (terpenes, peptides, alkaloids, polyketides and 
polysaccharides) followed by a brief description on their properties. In Table 2, 
some selected examples of bioactive MNP structures that belong to these 
classes are presented. 
 
Table 2: Selected examples of bioactive MNP structures belonging to the following chemical 
classes: terpenes, peptides, alkaloids, polyketides and polysaccharides.  
Chemical 
Classes 
Structure and Compound name Reference 
Terpenes  
 
Secomanoalide 
 [66]  
CHO
OH
O
HO
O
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Peptides 
 
Didemnin B 
 
[67]  
Alkaloids 
 
Nagelamide J 
[68] 
Polyketides 
 
Spongistatin 1 
[69], [70]  
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Polysaccharides 
 
κ-carrageenan 
[71], [72] 
 
2.1.1.1.Terpenes 

This class is considered one of the most diverse classes of metabolites, in 
their structure and number [73]. Terpenes are derived from a five-carbon 
isoprene structure and, depending on the combination of units, can be 
grouped into different biogenetic classes such as monoterpenes (C10), 
sesquiterpenes (C15), diterpenes (C20), sesterpenes (C25), triterpenes (C30, 
steroids) and tetraterpenes (C40, carotenoids). They can have several 
functional groups, e.g., isonitrile, dichloroimine, halogenated, isocyanate, 
among others. Several marine organisms produce terpenes, competing for 
space and reproduction – consequently, these compounds show bioactivities 
such as antibacterial and cytotoxic properties. For example, sesquiterpenes 
isolated from two seaweeds (Laurencia obtusa and Laurencia microcladia), 
collected from the North Aegean Sea, showed cytotoxic activity against five 
human tumor cell lines [74]. Scheuer et al. found that three metabolites 
belonging to sesterpene class, in which manoalide is the parent compound, 
displayed antibacterial activity against Gram-positive bacteria, i.e. 
Staphylococcus aureus and Bacillus subtilis [66].  
 
2.1.1.2.Peptides 

There has been an increasing interest in this class, since it offers a great 
potential for functional food and medical applications [75]. Bioactive peptides 
are specific protein fragments that act as sources of amino acids and 
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nitrogen, and have numerous potential physiological functions within the body 
[76], [77]. The sizes of bioactive peptides range from 2 to 20 amino acid 
residues in length and are encrypted within the sequence of parent protein. 
These peptides are inactive or latent in the parent, but are released in an 
active form by enzymatic hydrolysis. 
 
Marine bioactive peptides have shown diverse biological activities. For 
example, the depsipeptide didemnin B, first isolated from Caribbean tunicate 
Trididemnum solidum show significant antitumor activity and antiproliferative 
activity against human prostatic cancer cell lines [67]. Didemnin B is also the 
first MNP evaluated in human clinical trials. Matsunaga et al. [78] reported 
that a peptide discodermin A, isolated from marine sponge Discodermia 
kiiensis, showed antimicrobial activity against a range of Gram-positive and 
Gram-negative bacteria and fungi. A well-known compound belonging to this 
class is ziconotide, originally derived from a tropical marine cone snail and 
commercialized under the trade name Prialt® for the treatment of chronic pain 
in spinal cord injury (see Sub-chapter 2.5.1 for further details). 
 
2.1.1.3.Alkaloids 

Alkaloids are well known by their wide spectrum of biological activities [79], 
[80]. Pelletier et al. defined this class as “cyclic organic compounds containing 
nitrogen in a negative oxidation state which is of limited distribution among 
living organisms” [81]. They can be divided into seven subclasses: indole 
alkaloids, pyrrole alkaloids, pyridoacrine alkaloids, isoquinoline alkaloids, 
gadinine alkaloids, aminoimidazole alkaloids and sterol alkaloids [82]. Pyrrole 
alkaloids, especially bromopyrroles, are well known for being present in 
sponges, e.g. Agelas, Axinella, Acanthella, Hymeniacidon and 
Pseudoaxinyssa. Oroidin is a secondary metabolite from this subclass that 
exists in more abundance, being also the first one to be isolated [83], and it is 

2 A revised structure was established in 1973 and proven by total synthesis in 1986 [177]. 

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considered to be the biogenetic precursor of all the other bromopyrrole 
alkaloids. Nagelamide J, isolated from sponge Agelas sp. and the first 
bromopyrrole alkaloid possessing a cyclopentane ring fused to an 
aminoimidazole ring, showed antimicrobial activity against Staphylococcus 
aureus and yeast [68]. Nagelamide A, isolated as well from the same family, 
inhibited not only the growth of two Gram-positive bacteria but also Gram-
negative Escherichia coli [84].  
 
Tunicate-derived trabectedin, a secondary metabolite also belonging to the 
alkaloid class, is one of the marine-derived drugs that has passed cancer 
clinical trials [85]. More than 40 years after its discovery, it became the first 
marine anticancer drug to be approved in the European Union. 
 
2.1.1.4.Polyketides 

Polyketides are low molecular weight compounds assembled via sequential 
condensations of small carboxylic acids. Their sub-classes comprise 
polyethers, polyenes, polyphenols, macrolides and polyols, being mainly 
derived from the simplest (or one of the simplest) building blocks available in 
nature, i.e. acetic acid. From a pharmaceutical point of view, polyketides are 
an important source of novel drugs. Eribulin, a synthetic derivative of 
halichondrin B (natural polyketide) is one example of marine-derived 
anticancer drugs, approved by Food and Drug Administration (FDA) and 
European Medicines Agency (EMA). Spongistatin 1, a macrolide initially 
isolated from sponges Spirastrella spinispirulifera and Hyrtios [69], [70], 
display significant growth inhibition against a wide variety of cancer cell lines 
[86]. Macrolides (+)-brefeldin A, (+)-brefeldin C and 7-oxobrefeldin A, isolated 
from marine-derived fungus Penicillium sp. PSU-F44, have been described to 
show antimicrobial activity [87]. 
 
2.1.1.5.Polysaccharides 


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The majority of polysaccharides (PS) produced by marine organisms are 
heteropolysaccharides, i.e. complex carbohydrates composed of repeating 
units of several types of monosaccharides connected by glycosidic bonds. 
Mainly micro- and macroalgae contain PS, such as agar, alginates, agarose, 
carrageenans and fucoidans. There are several applications for PS, such as 
drug or nutraceutical carriers in pharmaceutical industry, thickeners and 
gelling agents in food industry, in soil and water treatments [88]. Review 
conducted by Raposo et al. [72], showed that crude PS and their derivatives 
can show anticoagulant, antitumor and anticancer activities and can also be 
potent antibiotic, antioxidant and anti-inflammatory agents. For example, 
carrageenan, a family of PS obtained by extraction from certain species of red 
seadweeds (Rhodophyta), have shown potential antiviral properties – Buck 
and coworkers demonstrated that by testing it against a range of sexually 
transmitted human papillomaviruses (HPVs) [71]. 
 
2.2. MNPs as scaffolds 

Nowadays, drug discovery is based on three major sources: NPs (natural 
products), semi-synthetic derivatives of NPs and synthetic compounds 
derived from combinatorial chemistry [89]. NPs can provide physicochemical 
properties such as specific interactions with multiple biological targets (barely 
found in molecules derived from combinatorial synthesis) and contain more 
chiral centers and a larger number of rings. However, the process from 
discovery to commercialization is complex, time-consuming and expensive, 
causing pharmaceutical industries to direct their drug discovery programs 
from NP-based research into synthetic pathways [90]. Since NPs generally 
have poor pharmacokinetics (but excellent bioactivity), using NPs as scaffolds 
for synthesis of new compounds can be pursued to improve the properties. 
Development of novel compounds by chemical synthesis includes 
modification/removal of functional groups and introduction of novel groups 
and stereocenters into the molecule. Sometimes, more radical changes in the 
scaffold are possible. One thing to keep in mind in the synthesis of new 

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compounds using MNPs as scaffolds is that marine compounds are typically 
very hydrophobic and this may become a problem further on in drug 
development [91]. 
An example of a structurally complex MNP that was used as scaffold for the 
design of new compounds is halichondrin B (Fig. 3), originally isolated from a 
Japanese marine sponge and firstly reported by Uemura et al. in 1985 [92], 
[93]. This compound had shown promising in vitro and in vivo anticancer 
activity and in 1992, total synthesis of this metabolite was reported [94]. In 
collaboration with Eisai Research Institute (Tokyo, Japan) work on the SAR of 
halichondrin B, a new synthetic analog was created – eribulin mesylate. 
Eribulin is commercialized under the trade name Halaven® for the treatment 
of metastatic breast cancer. Nowadays, this synthetic drug is also being 
studied for the treatment of other solid malignancies, e.g. advanced soft tissue 
sarcoma not responsive to radiotherapy and in patients who have not 
responded to hormone therapy. 
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Figure 3: Chemical structure of halichondrin B (top): the part of the molecule to make eribulin
mesylate is shown in blue. Chemical structure of eribulin mesylate (bottom, left). Japanese
sponge Halichondria okadai (bottom, right).  
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Another example of a lead compound used for the synthesis of new 
derivatives is bryostatin 1. This macrocycle, isolated from a bryozoan (aquatic 
invertebrate animal) ‒ Bulgula neritina [95] ‒ is known to present remarkable in 
vitro and in vivo activities related to cancer treatment, i.e., restoration of 
apoptotic function, reversal of multidrug resistance, among others [96]. Since 
economic and environmental factors limited further development of this 
source organism and its production, new functional derivatives (known as the 
bryologs) were made. These analogs exhibited greater in vitro and in vivo 
potency than the parent compound and have been tuned for clinical trials [96].  

2.3. Extraction of bioactive compounds: overview of sample 
preparation and extraction conditions 

Sample preparation and the following extraction are two of the most critical 
steps in the isolation of marine compounds, necessary for extracting the 
desired chemical components from the material for further separation and 
characterization. Firstly, marine organisms are collected from the selected 
environment. However, intrinsic (as genetic) and extrinsic (as environment) 
collection method, sampling (life cycle, season, day/night and preservation) 
should be taken into account. The most serious risks that can occur when 
sampling all type of organisms are contamination and cross-contamination. 
Once samples are collected, they should be quickly frozen with dry ice and 
stored at -20 ºC until processing in the shortest gap of time possible [97]. 
When in a laboratory, compounds should be isolated from marine organisms, 
following a procedure with several steps. Before starting any screening 
process, some objectives should be kept in mind when preparing extracts 
(crude or fractions) [98]: 
• steps should be taken to provide chemical stability of compounds in the 
extract; 
• efforts need to be made to minimize material losses; 
• sample preparation costs need to be minimized. 
 

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Choosing a method of extraction is dependent on the bioactive compound(s) 
to be isolated and features of the organism(s). Since the bioactive compounds 
of interest can be unknown, known or structurally similar to a group of known 
compounds, the extraction protocol should be clear and precise. Also, the 
success of an extraction process is affected by the content of bioactive 
compounds in the marine organisms: for example, algal protein content is 
higher in red macroalgae than in brown macroalgae. Thus, extraction of algal 
proteins is influenced by the chemical composition, morphological and 
structural characteristics, and content [99]. 
Generally, the extraction of bioactive compounds consists in the use of 
solvents with different polarities. The main advantages of using this type of 
extraction compared with other methodologies (for example, supercritical fluid 
extraction, ultrasound-assisted extraction) are low processing costs and ease 
of operation; disadvantages focus on the low selectivity and extraction 
efficiency, solvent residuals and environmental pollution [100]. Table 3 reports 
examples of bioactive compounds and the solvents commonly used for their 
extraction. 
 
Table 3: Solvents commonly used in extraction of bioactive compounds (adapted 
from: [101]). 
Type of bioactive 
compound 
Examples of bioactive 
compounds 
Solvents used 
(commonly) 
Polar organic 
compounds 
Alkaloids 
Aminoacids 
Polyhydroxysteroids 
Polyketides 
Saponins 
Shikimates 
Sugars 
n-butanol 
Methanol 
Ethanol 
Ethyl acetate 
Water 
Chloroform 
Acetone 
Medium-polarity 
compounds Peptides 
Dichloromethane 
Methanol 
Carbon tetrachloride 
Low-polarity 
compounds 
Fatty acids 
Hydrocarbons 
Fatty acids 
Carbon tetrachloride 
Hexane 
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Extraction by solvents can follow the principle of either liquid-liquid or solid-
liquid extractions. Kupchan’s extraction method [102] is probably the most 
popular liquid-liquid fractionation scheme. This method separates compounds 
based on their relative solubility in two different immiscible liquids. The 
selective partitioning of components of interest into one of the immiscible 
phases results from the choice of the most adequate extraction solvent. 
However, during the recent years, solid-liquid extractions have emerged as an 
alternative. There the material is placed in contact with a solvent, which 
diffuses into the cells, solubilizing the metabolites. After that, the metabolites 
are diffused out of the cells into the solvent. This extraction method has been 
commonly used for obtaining marine compounds, using a marine organism 
directly as a solid matrix [99]. 

2.4. Importance and approaches for screening bioactive compounds: 
general overview of bioactive screening  

Due to the great biodiversity in marine environment, the use of appropriate 
methodologies for biological screening of marine sources is of great 
importance. Basically, the selection of bioactivity screening assay depends 
mostly upon the target disease as well as the available information about the 
target marine source/organism. For example, if a marine source has some 
pharmacological history of use for a specific disease, we would rationally use 
a particular bioassay, which can show the known therapeutic activity, in order 
to isolate the active compound, which is accountable for that bioactivity. 
 
Whichever assay format is selected, the following factors need to be 
considered [103]:  
• Tolerance to several impurities available in crude extracts; 
• Sensitivity and capability to detect the presence of potentially active 
substances present in low concentrations (limit of 0.0001% of an active 
compound, based on the dry weight of extract); 
• Reproducibility and reliability; 

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• High throughput; 
• Tolerance to DMSO (commonly used solvent for solubilization of 
samples). 
 
During the primary biological screening, multiple samples are screened to 
evaluate whether any desired bioactivity is present. These types of assays are 
capable of providing results fast, not always quantitative, but economic. If a 
positive hit is observed in the primary screening, follow-up assays should be 
performed in order to eliminate false positives. Generally, a hit rate of ≤1% is 
considered reasonable from a primary screening for progressing to follow-up 
studies [104]. 
 
Secondary evaluation/confirmatory assays involve more exhaustive and 
comprehensive testing of active compounds. As a part of this process, 
consideration should be given to the properties of each compound, such as, if 
there is a SAR between the molecular structure and biological activity of the 
compounds. 
 
2.5. Marine drug discovery and development 

MNP discovery is a complex and multidisciplinary effort requiring work and 
interaction between marine biologists, chemists, microbiologists and 
pharmacologists. As it is known, the marine realm contains a rich variety of 
organisms, many of them under-investigated. Bioprospecting is a tool for 
biodiversity conservation, defined as the collection of biological material and 
analysis of its properties and/or its molecular, biochemical or genetic content 
for the purpose of developing a commercial product [105]. However, attention 
must be paid to ethical issues and conservation policies, since the loss of 
biodiversity is often associated with overexploitation and habitat degradation. 
In the last decades, discovery of new MNPs has exponentially increased, but 
the number of marine-derived molecules that are commercialized is still very 
low – eight approved drugs by FDA and/or EMA. Despite that, more than 20 
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marine products are in clinical trials and more than 1000 are in pre-clinical 
trials [106]–[108]. The process of R&D of new drugs is neither easy nor 
always successful; it is statistically shown [109] that of 5000 compounds that 
are discovered, only 5 progress to clinical studies and only 1 leads to an 
approved and commercialized drug (Fig. 4). 
 
A clinical trial is, per se, the testing carried out on human beings for 
determining its value for treatment or for prevention of diseases, involving a 
number of parameters. These parameters [110] include: the patient population 
to be studied (patients should meet specific criteria to ensure that they are as 
similar as possible to each other so that the results of treatments effect can be 
associated as much as possible with the drug treatment), use of controls 
[placebo (e.g., medically ineffectual treatment) or standard treatment (e.g., in 
wide use and considered effective at the time that the trial is designed)], 
endpoints (existence of a primary endpoint that usually assesses the 
treatment efficacy) and methods by which the trial will be conducted 
(randomly allocated to receive one or other of the alternative treatments being 
studied and/or partitioned by a factor other than the treatment, to ensure that 
equal number of patients with a characteristic thought to response to the 
intervention will be allocated to each comparison group).  

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Between Phase I and III, the potential of failing and withdrawals of drug 
development is high, mainly due to lack of efficacy and drug toxicity [111]. 
Upon authorization by the EMA/FDA, the therapies that have proven safety, 
efficacy and quality in the clinical trials may be made available to the general 
population. Still, EMA/FDA requires continued evaluation after release to 
evaluate safety signs that can affect the benefit-risk ratio [112], [113]. 
 
Discovery
Pre-clinical 
trials 
Clinical 
trials 
3-6 years  
6-7 years 
Approval for 
commercialization  2 years  
5000 compounds 
In vitro assays, 
Pharmacodynamics, 
Pharmacokinetics, Toxicology 
~250 compounds 
Phase I 
~5 compounds 
Phase II 
Phase III 
Approved 
drug 
Figure 4: The process of drug discovery and development – “The pipeline” 
(Adapted from: [109]). An Investigational New Drug Application (INDA) is 
submitted before the clinical trials and a New Drug Application is a sponsor’s 
request for approval of a drug for commercialization. 
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   
2.5.1. Commercial uses and applications of MNPs 

A large number of bioactive compounds found in marine organisms have 
proceeded into clinical trials and until 2014, eight FDA or EMA approved 
drugs originating from marine microbes are currently on the market [114]. For 
example, companies such as PharmaMar (Spain), AquaPharm Biodiscovery 
Ltd. (United Kingdom) or Nereus Pharmaceutical (United States of America) 
have several compounds in clinical trials, preclinical trials or even on the 
market. However, until now, only three compounds (Prialt®, Yondelis® and 
Carragelose®) have become drugs without modification of the original natural 
molecule, i.e. without any type of synthesis and optimization in the structure. 
Selected marine bioactive compounds in trials or commercialized from 2004 
until now are highlighted in Table 4.  
Phase I - 
Checking for 
safety 
Sample: 10-
20 healthy 
volunteers 
Side effects 
may occur 
Phase II - 
Checking for 
efficacy 
Sample: 
~200 patients 
High 
hypothesis of 
fail since 
product can be 
not so effective 
as expected 
Phase III - 
Confirm 
findings in 
large patient 
population 
Sample: 
more than 
1000 people 
Likelihood to 
detect rare 
side effects 
Phase IV - 
Testing long-
term safety in 
diverse 
patient 
population  
Sample: "real 
life patients" 
Previously 
untested 
groups can 
show adverse 
reactions 
Figure 5: Different stages of clinical trials (Adapted from: [180]). In Phase IV, active 
post-marketing surveillance of drug side effects is essential. 

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Cytarabine and vidarabine were the first marine-derived drugs approved by 
the FDA, as anticancer (1969) and antiviral (1976) drugs [115], respectively. 
Cytarabine (Cytosar-U®) is used for the treatment of two types of leukemia 
(myeloid and meningeal) and non-Hodgkin’s lymphoma. However, this drug 
has a short plasma half-life, low stability and limited bioavailability. Vidarabine 
(Vira-A®), has been used as an antiviral drug for the treatment of 
keratoconjunctivitis, an epithelial keratitis caused by the herpes simplex virus, 
but it has been discontinued by FDA in the US market because of its side 
effects such as fever, sore or other signs of infection. Another compound 
included in the same group as cytarabine and vidarabine based on their 
mechanism of action (DNA interaction), is trabectedin (Yondelis®). 
PharmaMar markets Yondelis® in Europe and Japan and new clinical trials 
have been carried out for breast and prostate cancer. The active ingredient 
was originally isolated from a Caribbean sea squirt called Ecteinascidia 
turbinata and it shows potent antitumor [116], [117] and antiproliferative [118] 
activities towards cancer cells. 
 
Prialt®, a ziconotide (synthetic derivative of ω-Conotoxin MVIIA) is being used 
for the treatment of chronic pain in the spinal medulla [11]. This compound 
was isolated from the marine snail Conus magnus in 1979. However, the 
complete synthesis was only finalized in 1987 [11]. Recently, a synthetic 
derivative of halichondrin B, eribulin mesylate (Halaven®) gained FDA’s 
approval for the treatment of metastatic breast cancer (Sub-chapter 2.2). 
 
An Austrian company, Marinomed Biotechnologie GmbH, has developed an 
antiviral nasal spray containing Iota-carrageenan (Carragelose®). This 
copolymer derives from carrageenan, high molecular weight sulphated 
polysaccharide extracted from red edible seaweeds, such as Rhodphyceae 
sp. This substance is clinically effective against early symptoms of the cold 
and is marketed as an OTC (over-the-counter) product. 
 

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Lovaza®, an anti-hypertriglyceridemia drug, is commercialized by 
GlaxoSmithKline and consists of a mixture of eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA). The approach to this drug discovery was 
based on studies stating that some ethnic populations, such as Native 
Alaskans, had much lower mortality rates from cardiovascular diseases, 
assumingly due to their diets that were high in polyunsaturated fatty acids 
[119]. Other studies confirmed also that ingesting omega-3 fatty acids was 
associated with a reduced rate of premature cardiovascular deaths [120], 
[121]. 
 
The latest marine-derived drug to enter the market until now was brentuximab 
vedotin (AdcetrisTM), consisting of an antibody brentuximab and monomethyl 
auristatin (vedotin), a synthetic analog of dolastatin 10. Dolastatin 10 is a 
compound originally isolated from the marine mollusk Dolabella auricularia 
[122]. Of the antibody-drug conjugate, the chimeric monoclonal antibody 
brentuximab targets the CD30 antigen on the surface of malignant cells, 
leading to the uptake of vedotin (an antimitotic agent) into the targeted cells. 
Brentuximab vedotin is used for treating Hodgkin’s lymphoma and systemic 
anaplastic large-cell lymphoma. 
 
  

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3. Aims of the study 
 
The aim of this study was to evaluate, using in vitro assays, the biological 
activity of extracts and synthetic compounds derived from marine organisms. 
NPs, especially those from terrestrial plants and microbes, have been the 
most successful sources of potential drug leads. MNPs have only become a 
“hot topic” in the last decades, as a consequence of their proven potential as 
antimicrobial, anticancer, antiviral and anti-inflammatory agents, among other 
properties. The studies included in this thesis focused on the assessment of 
biological potential of marine-derived substances that can have a significant 
impact in the pharmacological field during the coming years. 
 
The specific aims of this doctoral thesis were: 
• to study the biological properties of synthetic derivatives designed by 
using marine alkaloids oroidin and clathrodin as parent structures (I, II); 
• to determine the biological activities of synthetic crown acyl ether 
derivatives, developed by using okadaic acid structure as inspiration (III); 
• to evaluate the bioactive potential of cyanobacteria, micro- and 
macroalgae extracts originating from the Aegean Sea (IV). 
 
  

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4. Material and Methods 
 
Microbial strains and cancer cell lines used in this study are listed in sub-
chapters 4.1 and 4.2. Types of biological assays used are listed below. 
   
Table 5: Biological assays used in studies (I)-(IV). 
Biological assays Methods Study 
Anti-inflammatory  
Cytokine analysis 
Flow cytometric analysis 
IV 
Antifouling  Agar diffusion IV 
Antimicrobial  
Agar diffusion IV 
Broth microdilution I, II, III, IV 
Antiproliferative/Cytotoxicity 
ATP assay I ,IV 
LDH assay II 
MTT assay II, IV 
Sulforhodamine B assay III 
Antiviral HCV replicon supression1 II 
1 An HCV replicon model [124] was used in this assay. 
 
4.1. Microbial strains and growth conditions 

Four human pathogenic strains were used in the antimicrobial study: two 
Gram-positive bacteria (Enterococcus faecalis ATCC 29212 and 
Staphylococcus aureus ATCC 25923), one Gram-negative bacterium 
(Escherichia coli ATCC 25922) and one fungus (Candida albicans ATCC 
90028). Brief descriptions of these pathogens are shown in Table 6. All strains 
were obtained from Microbiologics Inc. (USA). Strains were stored long-term 
at -70 ºC and used as needed. Bacterial strains were grown on MHA (Becton 
Dickinson, USA) and C. albicans on SDA (Becton Dickinson, USA) at 37 ºC 
and 28 ºC, respectively. All stock cultures were maintained at 4 ºC.
 

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4.2. Cell lines and culture conditions 

For antiproliferative and cytotoxicity studies, the following cell lines were used: 
A-375 (human malignant melanoma) and BALB/c 3T3 clone A31 (embryonic 
mouse fibroblast). A-375 was kindly provided by Prof. Marikki Laiho 
(University of Helsinki, FI) and BALB/c 3T3 clone A31 was obtained from the 
European Collection of Cell Cultures (ECACC, UK). Melanoma cells were 
grown in Glutamax DMEM with 4.5 g/L D-glucose (Gibco, USA), 
supplemented with 10% FBS (Gibco, USA), 100 IU/mL penicillin (Gibco, USA) 
and 100 μg/mL streptomycin (Gibco, USA). BALB/c 3T3 cell line was cultured 
in DMEM (Sigma-Aldrich, USA), supplemented with 5% FBS (Gibco, USA), 
5% NCS (Gibco, USA), 292 μg/mL L-glutamine, 100 IU/mL penicillin and 100 
μg/mL streptomycin. 
 
Methods related to human breast epithelial (HBL-100), human cervical cancer 
(HeLa), alveolar carcinoma (SW1573) and colon adenocarcinoma (WiDr) cell 
lines are described in detail in Publication (III). To prostate cancer (LNCa, PC-
3), breast cancer (MCF-7) and non-tumorigenic epithelial (MCF-10A) cell 
lines, methods are described in Publication (IV). 
 
4.3. Reference compounds 

Stock solutions of amphotericin B (Sigma-Aldrich, USA) and ciprofloxacin (MP 
Biomedicals, USA) were made in DMSO and milliQ water, respectively. The 
reference antibiotics were used for assay validation and as positive controls in 
the antimicrobial assays. Stock solutions of polymyxin B sulphate (PMX, 
Sigma-Aldrich, DK) were diluted in milliQ water and assays were validated. 
PMX was used as positive control in antiproliferative assays.

4.4. Marine test material 

A set of marine natural products and marine-derived compounds were used in 
experiments and evaluated for their antimicrobial and antiproliferative 

46 
properties. In publications I, II and III, the following sets of marine-derived 
synthetic compounds were studied: 
• (I): set of thirty-four novel analogs, using oroidin as scaffold; 
• (II): set of fourteen new clathrodin-inspired 2-aminobenzothiazole and 
benzimidazole derivatives and their synthetic intermediates; 
• (III): set of twenty-two macrocyclic compounds, employing secondary 
metabolite okadaic acid (OA) as inspiration. 
In the last publication (Study (IV)), ninety-eight crude extracts (solvent used in 
extraction: ethanol) of cyanobacteria, micro- and macroalgae originating from 
the Aegean Sea were studied.  
 
Methods related to the synthesis and chromatographic analyses of the 
compounds are described in detail in Publications (I), (II) and (III). 

4.5. Screening for bioactivity 
4.5.1. Antimicrobial screening 

Broth microdilution 
Broth microdilution method was used in all studies (I, II, III, IV). Together with 
agar dilution, it is the standard susceptibility testing method approved by 
EUCAST [126] and CLSI [127]. Briefly, the bacterial or fungal strain to be 
used in the assay was inoculated the day before on MHB or SDA, 
respectively, and grown for 16-24 h. For the experiment, CFU/mL was 
calculated and suspensions prepared, based on the absorbance values at 
620 nm, previously calibrated against plate counts. Compounds were diluted 
into the assay media, and dispensed into clear 96-well microplates (Thermo 
Fisher Scientific, FI) and the bacterial/fungal suspension added to the plates. 
The assay plates also included the positive control antibiotics: amphotericin B 
for C. albicans and ciprofloxacin for bacterial strains (MICs are mentioned in 
the articles). The plates were incubated for 24 h at 37 ºC for bacteria and 48 h 
at 28 ºC for Candida. Synthetic compounds and extracts were initially 
screened at the final concentration of 50 μM and 100 μg/mL, respectively. 

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Samples that demonstrated potent activity (growth inhibition >50%) were 
selected for confirmatory testing (dose-response) and MIC determination. 

4.5.2. In vitro antiproliferative and cytotoxicity screening 

The general procedures for routine subculturing and exposure of cells to 
compounds are found in publications (I) and (II). In Study (I), Huh-7 (human 
hepatocellular carcinoma) cell line was used for selectivity studies. In Study 
(II), two cell lines were used: A-375 (human malignant melanoma, epithelial, 
cancer) and BALB/c 3T3 clone 31 (embryonic mouse fibroblast, non-cancer).  
Melanoma is a cancer that involves the melanocytes (specialized pigment 
cells) in the basal layer of epidermis and is one of the most common and 
aggressive forms of skin cancer and related deaths. This “fatal black tumor” 
[128] displays a growth of incidence in most populations of Caucasian origin 
[129]; in Europe, the highest incidence rates of melanoma are reported in 
Scandinavian countries [130]. The main environmental factor, UV light 
exposure, can cause damage in keratinocytes and melanocytes synthesize 
melanin (protective pigment). If exposure to UV is extreme, keratinocyte 
population can die but melanocytes survive – due to efficient DNA damage 
repair response ‒, having the chance of developing mutations [131], [132]. 
BALB/c 3T3 non-cancerous cell line was used in publication II as a model for 
selectivity studies in comparison with melanoma cell line.  
 
ATP assay (I) 
Adenosine triphosphate (ATP) is indicative of metabolically active cells, as it is 
responsible for intracellular energy transfer [133]. Non-viable cells are not 
metabolically active, and therefore do not produce ATP. CellTiter-Glo® 
Luminescent Cell Viability Assay (Promega Corporation, USA) was used to 
study the effect of the most promising compounds on the metabolic activity of 
Huh-7 cells. This assay is based on luciferase reaction that produces light in 
the presence of ATP, and is thus used for measuring the intracellular ATP 
content. After the exposure of cells to compounds, cells were washed with 
phosphate buffered saline (PBS) and 50 μL of assay media and 50 μL of 

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CellTiter-Glo reagent were added. After plate shaking for 2 min and incubation 
at room temperature (rt) for 10 min, the luminescent signal was determined 
using a Varioskan Flash Plate reader (Thermo Fisher Scientific, FI). 
Cytotoxicity (%) was calculated by normalizing to vehicle-treated control 
values. 
 
MTT assay (II) 
MTT assay [134], [135], based on MTT dye [3-(4,5-dimethyl thiazol-2-yl)-2,5-
diphenyl tetrazolium bromide], was used to estimate the cytotoxic effects of 
compounds. This assay is based on the conversion of MTT to formazan 
crystals by reduction, catalyzed by intracellular dehydrogenases and it is 
widely used for measuring in vitro cytotoxicity. Briefly, after the adhesion of 
cells to 96-well microplates (Thermo Fisher Scientific, FI) and treatment with 
compounds (duration of 24 h), 10 μL of 5 mg/mL MTT stock solution (Sigma-
Aldrich, USA) in sterile PBS was added to the cells. Following 3 h incubation 
in a humidified atmosphere (37 ºC, 5% CO2), the medium was removed and 
the blue formazan crystals trapped in the cells were dissolved in 200 μL of 
DMSO. The plates were agitated until formazan had completely dissolved. 
The absorbance at 550nm/655nm was measured with Multiskan® GO UV/Vis 
spectrophotometer (Thermo Fisher Scientific, FI). Cytotoxicity (%) was 
calculated by normalizing to vehicle-treated control values. 
 
LDH assay (II)
Leakage of intracellular lactate dehydrogenase into culture medium can be 
measured by LDH leakage assay. The activity is measured by monitoring the 
rate at which the substrate (pyruvate) is reduced to lactate. Its evaluation is 
based on the decrease of membrane integrity to retain the enzyme in the 
cytoplasm when cells are exposed to toxic agents [136], [137]. The more 
damaged a cell membrane is, the more leakage of LDH occurs. The CytoTox-
ONE-Homogeneous Integrity Assay Kit (Promega, USA) was used for 
measuring LDH leakage. After exposure of cells to compounds, 50 μL 
samples from culture supernatants were transferred into sterile, white and 

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clear-bottom 96-well plates (PerkinElmer Inc., USA). After 20-30 min of 
incubation at room temperature (rt) in dark, 50 μL of CytoTox-ONE reaction 
mixture was added to the plates and shaken for 10 min. The enzyme reaction 
was stopped with 25 μL CytoTox-ONE stop solution. After plate shaking for 
10s, fluorescent signal was measured at a wavelength of 560 nm (excitation) 
and 655 nm (emission) with a Varioskan Flash Plate reader (Thermo Fisher 
Scientific, FI). The % of LDH leakage was calculated by normalizing to 
vehicle-treated control values. 
 
4.6. Selectivity index  

Selectivity index (SI), also known as therapeutic index (TI), is an important 
criterion that determines which compounds will advance further in laboratory 
and clinical studies. It is considered a quantitative relationship between their 
efficacy (pharmacology) and safety (toxicology). In Study (I), the selectivity 
was based on the effects between eukaryotic (IC50) and prokaryotic (MIC50) 
cells. In Study (II), the ratio between a normal cell line (IC50) and a cancer cell 
line (IC50) was used to measure this index. 
 
4.7. Data analysis  

All data presented are means ± SD. Data were analyzed using Microsoft 
Office Excel 2010 and the IC50 values were determined using Origin Graphing 
and Analysis, version 8.6 (OriginLab, USA). All experiments were performed 
at least in triplicate. 
 
4.8. Quality parameters 

Three types of quality parameters were used for evaluating the quality of the 
results: Z’, S/B and S/N. The data quality of the assays can be estimated by 
the following formulas [138], [139]  
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, where 
  and   are the mean and standard deviation for the high 
reference control samples (maximum) and 
 and  are the mean and 
standard deviation for the low reference control samples (i.e. background).  
 
Z’ factor is used as a screening quality assurance parameter and it is the most 
practical factor to use when evaluating assay quality. Z’ close to 1 is 
considered an ideal assay and values between 0.5 and 1 are considered of 
good quality. In general, if Z’ value is lower than 0.5, the assay is considered 
of low quality and should be repeated (for cell-based assays, threshold 0.3 or 
0.4 is sometimes considered acceptable). The S/B (signal-to-background) and 
S/N (signal-to-noise) ratios should also be taken into account since they 
reflect the assay signal strength. The S/B ratio evaluates the strength of signal 
in comparison with background measurements (S/B5, good quality) and S/N 
ratio signifies the strength of signal in relation to the noise (high S/N desired if 
S/B is low) [140]. 
 
 
 
 
 
 
 
 
 
 

51 
5. Summary of Results and Discussion 
 
This chapter of the thesis summarizes the main results of the work. More 
details can be found in the original publications (I-IV). 
 
Articles (I), (II) and (III) focus on biological studies of synthetic derivatives. 
The innovations and advances in marine research have contributed to the 
perception that MNPs can be considered as privileged structures or 
biologically validated stating points for the design of new compounds. Article 
(IV) shows results from a large-scale screening programme of bioprospecting 
of species from the Aegean Sea, where several crude extracts from 
cyanobacteria, micro- and macroalgae were evaluated for biological activities. 
Marine ecosystems and rarely explored places such as the Aegean Sea that 
contains a rich biodiversity of marine organisms can be particularly suited for 
bioprospecting, a process that aims to identify and isolate bioactive natural 
compounds. 
 
5.1. Oroidin and clathrodin as parent structures for synthesis of new 
compounds (I), (II) 
5.1.1. Antimicrobial studies (I), (II) 

Clathrodin is a secondary metabolite isolated from Caribbean sponge Agelas 
sp. that belongs to a class of alkaloids, pyrrole-imidazole alkaloids (PIAs). 
These metabolites contain 2-aminoimidazole, pyrrole amide structures, and 
are rarely found in terrestrial flora and fauna. Oroidin, an achiral and 
monomeric product also used in Study (I), is generally considered the 
biogenetic precursor of other alkaloids from the same family. Within the PIA’s, 
oroidin and clathrodin (Figure 6) are believed to be one of the basic 
biosynthetic units for the construction of more complex and larger analogs. 
Oroidin, for example, due to its low molecular mass and simple structure, is 
believed to offer several possibilities for chemical optimization, with the 
introduction of additional side chains/functional groups. 

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Neither oroidin nor clathrodin has been intensively studied until now. 
However, both secondary metabolites have rekindled interest in synthetic 
chemistry due to their intricate structural complexity and spectrum of 
bioactivities, including antimicrobial [141], cytotoxic [142], antimuscarinic [143] 
and voltage-gated sodium channel blocking ability [144]–[146]. 
 
The antimicrobial activity and cytotoxic effects of thirty-four synthesized 
derivatives using marine alkaloids clathrodin 2a(I) and oroidin 2b(I) as 
scaffolds were evaluated in Study (I). The compounds belong to four different 
structural classes, i.e.:  
• compounds 2a(I)-2d(I): 4-(3-aminoprop-1-en-1-yl)-2-aminoimidazoles; 
• compounds 5a(I)-5c(I), 5f(I)-5l(I), 6a(I)-6l(I), 7(I) and 8(I): 4-phenyl-2-
aminoimidazoles; 
• compounds 10a(I)-10c(I) and 11a(I)-11c(I): 4-phenyl-4,5-dihydro-(N-
methylamino)-imidazoles; 
• compounds 15(I) and 16(I): 1-benzyl-4-phenyl-2-aminoimidazoles. 
 
Clathrodin 2a(I) did not show any relevant activities at a concentration of 50 
μM, against all the microbial strain in the primary screening. On the other 
hand, its analog, oroidin 2b(I), displayed promising activity against Gram-
positive bacteria in the primary screening (Article (I), Figure 3) and because of 
that, new oroidin derivatives with indole and substituted indole rings were 
designed and prepared. Table 7 shows the chemical structures and 
antimicrobial dose-response data for 4-phenyl-2-aminoimidazoles 6g(I) and 
Figure 6: Chemical structures of pyrrole-imidazole
alkaloids, clathrodin (R = H) and oroidin (R = Br). 
N
N
H
H2N
N
H
H
N
R
R
O
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6h(I) that were active (>80% inhibition of growth) in the primary screening. 
Both obtained the best results against Gram-positive bacteria; compound 
6h(I) showed MIC50 of 8.0 and 7.3 μM with Enterococcus faecalis and 
Staphylococcus aureus, respectively. 
In a study conducted by Zidar et al., synthetic compounds belonging to the 
same structural class acted as state-dependent voltage-gated sodium channel 
modulators and have shown interesting activities with moderate isoform 
selectivities [147]. 
Hammami et al. have shown that oroidin display antifungal activity against 
Alternaria solani, a plant pathogen [148]. In a study conducted by Scala et al, 
two analogs of oroidin (dispacamide B and spongiacidin) have displayed 
antimalarian activity (IC50 of 1.34 and 1.09 μg/mL, respectively) against a 
protozoa belonging to the genus Plasmodium [149]. In the same study, a 
dimeric derivative of the same parent compound (dibromopalaumine) has 
been identified as a trypanocidal agent, showing an IC50 of 0.46 μg/mL [149]. 
In another recent article, oroidin and clathrodin were found to be weakly active 
when tested for apoptosis-inducing activities against the human hepatocellular 
carcinoma (HepG2) cell line; however, some of the indole-based analogs 
showed promising activities, with EC50 values between 13 and 42 μM [150]. 
 
The importance of an imidazole ring in the chemical structure of a compound 
for antimicrobial activity was also found in this study. For example, 
compounds 10a(I)-c(I) and 11a(I)-c(I) did not show any antimicrobial activity; 
these compounds have in their chemical structure a reduced imidazole  
bond. The incorporation of imidazole ring can result in exhibition of a wide 

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spectrum of biological activities [151]–[154]; its unique structural feature is 
valuable for derivatives to bind with receptors in biological systems. 
 
In Study (II), clathrodin was used as an inspirational structure for the 
synthesis of fourteen new benzimidazole and 2-aminobenzothiazole analogs. 
Benzimidazole, a heterocyclic aromatic compound that consists of the fusion 
of benzene and imidazole, has been used as nucleus structure of various 
drugs and is known for its biological activities [155]–[157]. Benzothiazole is 
considered a privileged bicyclic ring system due to its potent and significant 
biological activities of pharmaceutical importance [158], [159]. A derivative of 
2-aminobenzothiazole, compound 7(II), showed 56% growth inhibition against 
Gram-positive E. faecalis in the primary screening. In dose-response assay, 
the inhibition did not reach MIC90 level (even at the highest concentration 
tested), concluding that an optimization of the compound structure should be 
made in order to improve its properties. 

5.1.2. Antiproliferative (I), (II) and antiviral studies (II) 

In Study (I), the metabolic activity of Huh-7 hepatocytes after exposure to the 
most promising antimicrobial compounds was evaluated by intracellular ATP 
quantitation. This test is based on a luciferase reaction to measure the 
amount of ATP in cells, correlating directly with the number of cells and their 
viability because cells lose the ability to synthesize ATP directly after e.g. loss 
of membrane integrity or other cytotoxic event. Most of the derivatives that 
were active in antimicrobial assays, showed also an effect on eukaryotic cells. 
4-phenyl-2-aminoimidazole 6j(I) showed the most interesting IC50 (19.8 μM) 
while the compounds that had the best antibacterial results, i.e. 6g(I) and 
6h(I), showed only moderate IC50 of 31 and 21.2 μM, respectively, against 
eukaryotic cells. 
 
In Study (II), the antiproliferative activities of compounds were studied against 
a human cancer cell line and a normal cell line: A-375 (melanoma) and 

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BALB/c 3T3 (fibroblast). MTT and LDH assays were used in the experiments. 
The hydrogen acceptor 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyItetrazolium 
bromide (MTT) is commonly used to estimate cell viability (and therefore 
cytotoxicity) in drug screening, while LDH is the most common cytotoxicity test 
used to measure the release of intracellular enzymes into culture medium 
[136]. 
Results from MTT primary studies with melanoma cell line showed that N-((2-
aminobenzo[d]thiazol-6-yl)methyl)benzamide 4a(II) and (9H-fluoren-9-
yl)methyl [(2-aminobenzo[d]thiazol-6-yl)methyl]carbamate 7(II), both 
derivatives of 2-aminobenzothiazole showed cytotoxicity above the threshold 
of 50%. In confirmatory dose-response experiments, only for compound 7(II) 
the cytotoxic effect was clear, yielding an IC50 of 16 μM (Fig. 7a)). This 
compound also caused elevated intracellular enzyme leakage at the highest 
concentration tested (Fig. 7b).  
In results using BALB/c 3T3 clone A31 as non-cancerous cell line for 
selectivity studies, the IC50 of compound 7(II) was higher (71 μM) than against 
the A-375 melanoma cell line. The effect in LDH leakage assay followed the 
same trend, where an increasing leakage was observed at concentrations 
higher than 75 μM (the effect of the positive control, PMX at 20 000 IU/mL 
was 2.1-fold increase). 
 
 
 
 
 
 
 
 
 
 
 
a) 
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When comparing both tests used for cytotoxicity assessment, MTT appears to 
be an earlier indicator of cytotoxicity compared with LDH test. Also, the most 
active compound not only in antiproliferative screening against melanoma and 
fibroblast cell lines, but as well in antimicrobial screening was compound 7(II), 
as stated previously. This compound is an intermediate and not a final amide, 
suggesting that the length of the linker chain is not optimal. When comparing 
with Study (I), where bulky 4-phenyl-2-aminoimidazoles were the most active, 
is possible to say that probably bulkier lipophilic groups than pyrrole are 
preferred on the right side of the molecule. 
 
To study the antiviral properties of compounds 2b(II)-18(II) against hepatitis C 
virus (HCV) replication, a replicon cell line in which a HCV replicon is co-
expressed in a hepatocyte derived cellular carcinoma (Huh-7) cell line with 
firefly luciferase (marker protein) was used. Luciferase expression was 
measured using a Firefly Luciferase Assay Kit (Promega, USA) and 
Figure 7: a) Dose-response curves of compound 7(II) against human melanoma cell line A-
375, by MTT assay. Results are expressed as percentage of cytotoxicity. b) LDH leakage in 
A-375 human melanoma cells and BALB/c 3T3 clone A31 fibroblast cells after compound 
7(II) exposure. Results are expressed as percentage of intracellular lactate dehydrogenase 
leakage. Data are the means from three independent experiments. 
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cytotoxicity effect was determined using a CellTiter GLO® Luminescent Cell 
Viability Assay Kit (Promega, USA). The methods are explained in detail in 
Article (II). 
Compounds 4d(II) and 7(II) showed HCV replicon inhibition of 73% and 86%, 
respectively. However, when measuring the viability of cells after treatment 
with compounds, it was shown that both had cytotoxic effects on the HCV 
replicon host cells; therefore, the antiviral properties were not studied further. 

5.1.3. Selectivity studies 

To determine the selectivity of a compound between different cell types, a 
selectivity index (or therapeutic index) was used in both studies: 
• Study (I): eukaryotic cells vs prokaryotic cells; 
• Study (II): embryonic mouse fibroblast cell line (BALB/c 3T3 clone A31) 
vs human malignant melanoma cell line (A-375). 
In drug discovery, this parameter is useful for selecting candidate compounds 
for further development or in the characterization of lead compounds. 
 
The most active synthetic analogs from Study (I) in antimicrobial studies 
showed in general nonselectivity towards prokaryotic cells: the majority of SI 
values were under 5. However, 5-chloro-indole derivative 5i(I) and 4-phenyl-2-
aminoimidazole derivative 7(I) displayed selectivity towards prokaryotic cells 
(i.e. S. aureus), with SI values higher than 8, close to minimum threshold to 
be selected for further testing [160]. With further structural optimisation of the 
analogs that showed higher antimicrobial selectivity against Gram-positive 
bacteria, these compounds could be useful for further development. 
 
When estimating the SI of compound 7(II), results exhibited a moderate level 
of selectivity, around 4. In a study performed by Delgado et al. [161] , two 
amiquinones structurally related to marine isoquinoline quinones, showed SI 
between 1.3 and 3.7 and were selected as promising lead compounds. 
According to Suffness et al. [162], the selectivity index for anticancer effects is 

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interesting even at values equal or greater than two. Therefore, (9H-fluoren-9-
yl)methyl [(2-aminobenzo[d]thiazol-6-yl)methyl]carbamate 7(II) should be 
considered promising for further development towards new anticancer agents. 
 
5.2. Okadaic acid as inspiration for macrocyclic synthetic compounds 
(III) 

Following the line of Study (I) and (II), Study (III) originated from the 
preparation of compounds having protein-okadaic acid (OA) structure as an 
initial inspiration. OA binds adopting a structure of a macrocycle that interacts 
with the metal atom of the protein and a hydrophobic tail. Additionally, OA 
binds potassium ions – their presence seems to be a requirement for 
biological activity [163]–[165]. Aiming to find a simple way to synthesize 
molecules mimicking the properties of OA, crown ethers were used. Before 
any biological studies, computational methods showed promising results 
between the crown ether acyl derivatives created and the receptor protein. 
 
Since Pedersen’s discovery of crown ethers in 1967 [166], the study of crown 
ethers have attracted attention thanks to their powerful noncovalent 
interaction properties, not only in chemistry but also in the fields of 
pharmacology [167], [168] and medical imaging [169], [170]. 
Crown ethers are macrocyclic compounds constituted by organic rings, 
normally with more than 12 atoms in the cycle, and having oxygen, nitrogen, 
sulphur or other heteroatoms. They are named as x-crown-y where “x” 
denotes the total number of atoms in the cyclic backbone and “y” denotes the 
number of oxygen atoms. The classic ones contain between 3 and 20 oxygen 
atoms, separated from each other by two or more carbon atoms.  
There are studies that show the use of crown ethers as systems to mimic 
biological processes based on molecular recognition, since these 
macrocycles behave very similarly to natural ionophores (such as gramicidin) 
and exhibit an exceptional versatility in selective binding to a variety of ions. 

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This capacity of molecular recognition and mimic behaviour enhances the 
application of crown ethers in the biomedical field [167]. 
 
 
 
The twenty-two synthesized compounds in Study (III), were macrocyclic, i.e., 
molecules with ring architecture of 12 or more atoms. Since macrocyclic 
compounds are more stable thermodynamically and kinetically, they have 
captured the attention of synthetic chemists for the development of new 
compounds. In this study, the antimicrobial and antiproliferative effects of the 
crown ether acyl derivatives, based on an 18-crown-6 moiety (Study (III), 
Figure 1), were determined. 
 
5.2.1. Antimicrobial studies 
 
Based on antimicrobial data, (1,4,7,10,13,16-hexaoxacyclooctadecan-2-
yl)methyl 3-(pyren-1-yl)propanoate 1o(III) was the most active against Gram-
positive S. aureus and fungus C. albicans, presenting a full inhibition for both 
strains in the primary screening and MIC50 of 7.2 μM and 39 μM, respectively 
(Figure 9 and Table 8). Against Gram-negative bacterium, no significant 
activity was shown, possibly due to the molecular composition and presence 
of an outer membrane. Only scarce data on antimicrobial properties of crown 
ether derivatives have been previously reported. However, Leevy et al. [171] 
showed that antibacterial activity against E. coli is altered by the spacer 
length. 
 
Figure 8: Examples of crown ethers, with increasing ring size (from left to
right): 12-crown-4, 15-crown-5 and 18-crown-6 ether.  
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5.2.2. Antiproliferative studies 

To determine the in vitro antiproliferative activity of the derivatives, the 
following human cell lines were used: human breast epithelial (HBL-100), 
human cervical cancer (HeLa), alveolar carcinoma (SW1573) and colon 
adenocarcinoma (WiDr). The determination of GI50 (proliferation inhibition by 
50%) values by using the SRB assay, showed that (1,4,7,10,13,16-
hexaoxacyclooctadecan-2-yl)methyl anthracene-9-carboxylate 1p(III) 
displayed promising activity, with values in the range of 3.7-5.6 μM (Study  
(III), Table 1). However, in antimicrobial studies, this compound showed a 
moderate MIC50 of 20 μM against S. aureus. Further, the most active 
compound against S. aureus ((1,4,7,10,13,16-hexaoxacyclooctadecan-2-
yl)methyl 3-(pyren-1-yl)propanoate 1o(III) showed only moderate GI50 against 
all cancer cell lines.

Figure 9: Dose-response curves of compound 1o(III)
against S. aureus (square) and C. albicans (triangle).
Results were expressed as % of growth inhibition. 

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In a study conducted by Supek et al. [172], it was shown that the lipophilicity 
coefficient (logP) of 18-crown-6 ethers is considered an important molecular 
descriptor in determining biological potency. In Study (III), calculated logP 
values for four compounds showed values higher than 3 (Article (III), Table 1). 
However, the value was not directly correlated with the observed biological 
activity.  

Nevertheless, the results obtained may enhance the understanding of 
biological effects of crown ether derivatives studied and thus provide 
information for synthetic optimization that can lead to novel antimicrobial and 
antiproliferative agents. 


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5.3. Bioprospecting focused on the Aegean Sea (IV) 

While the Mediterranean Sea is considered a marine biodiversity hotspot 
[173], the Aegean Sea is still an untapped and mostly unstudied source of 
potentially bioactive species. Marine bioprospecting is, per se, a targeted and 
systematic search for components, bioactive compounds or genes within 
marine organisms. From the business perspective, the purpose of 
bioprospecting is to find compounds that may be included as components in 
products or processes. In this study, five different steps were employed, as 
illustrated below:  

A large-scale biological screening of 98 specimens collected from the Aegean 
Sea located between the mainlands of Greece and Turkey was conducted in 
Study (IV). Samples were evaluated for antimicrobial, anticancer, antifouling 
and anti-inflammatory properties altogether in 32 different assays. The crude 
extracts originated from organisms such as cyanobacteria, micro- and 
macroalgae. Cyanobacteria, micro- and macroalgae are known for their 
potential to produce biologically active components (described in detail in 
Chapter 2). The number of active extracts (threshold = 50%) per phyla is 
presented in Table 9. 
 
Table 9: Number of active extracts (% inhibition > 50) in each phyla.  
Phyla % extracts Nr. active extracts 
Cyanobacteria 7 0 
Chlorophyta 27 3 
Collection of 
specimens Isolation
Batch 
cultivation
Preparation 
of extracts
Biological 
screening
Figure 10: Procedures performed for the discovery of bioactive species. Cyanobacteria and
microalgae species were cultivated in batch cultures. 
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Bacillariophyta 7 3 
Haptophyta 1 0 
Ochrophyta 40 9 
Rhodophyta 16 5 
Tracheophyta 2 0 
 
5.3.1. Antimicrobial and antifouling studies 
 
Extracts derived from microalgae showed inhibition of microbial growth higher 
than 50%: Amphora cf capitellata 10S014 and Nitzschia communis 10S152 
fully inhibited fungus Candida albicans and bacterium Staphylococcus aureus, 
respectively, at a concentration of 100 μg/ml. Also, the first microalgae 
previously stated had an effect of inhibition against Gram-positive bacteria 
Enterococcus faecalis (68%) and S. aureus (83%).  
In antifouling studies, 2 macroalgae species belonging to a same genus – 
Cystoseira barbata 10S022-1(IV) and Cystoseira crinita 10S027(IV)  – 
showed moderate antifouling activity equal or higher than 57% against two 
marine bacteria, Alcanivorax sp. and Pseudoalteromonas sp. 
These preliminary results summarize the importance of algal extracts, which 
may have potential as antimicrobial agents and should be considered to study 
further, to isolate and identify bioactive compounds from the extracts. 
 
5.3.2. Antiproliferative studies 

Two prostate cancer (LNCa, PC-3), a breast cancer (MCF-7) and non-
tumorigenic epithelial (MCF-10A) cell lines were used in this work for 
evaluation of antiproliferative activity. 
While extracts of macroalgae extracts Dictyopteris membranacea 10S039(IV) 
and Hypnea musciformis (10S049(IV) and 10S053(IV)) showed growth 
inhibition higher than 60% for all the cell lines at 50 μg/ml, Cystoseira sp. 
(10S035(IV), 10S037(IV), 10S038(IV)), microalgae Nitzschia thermalis 
10S151, and red algae Laurencia papillosa (10157(IV)) and 10S041(IV)) only 

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showed significant cytotoxic effects against cancer cell lines (Study (IV), Fig. 
1). It has been reported that Nitzschia sp. can induce leukemia cell death 
(apoptosis) [174] and that polysaccharides extracted from D. membranacea 
have been demonstrated to be effective antitumor agents (IC50 of 9.83 μg/dL, 
HeLa cell line) [175]. Mhadhebi et al. [54] reported similar antiproliferative 
effects for aqueous extracts from Cystoseira sp., with different cancer and 
normal cell lines, exhibiting an IC50 between 17.9 and 29.5 μg/mL against 
MCF-7. 
These results suggest that the extracts that showed promising, selective 
results against cancer cell lines should be studied further.  
 
5.3.3. Anti-inflammatory studies 

Anti-inflammatory properties of the extracts were studied by using primary cell 
cultures and the following assays: 
• MTT reduction assay: used for evaluating the effects on neuronal cells 
and astrocytes. Data are presented as percentage of survival/activation 
of treated versus untreated cells; 
• MHC class-I and MHC class-II antigen expression: used for flow 
cytometric analysis, using a FACScan flow cytometer (Becton Dickinson, 
USA); 
• Determination of cytokine concentration: supernatants obtained from 
microglial cell cultures were analyzed for TNF-, IL-1, IL-4, IL-6, IL-8, 
IL-10, and IL-18 cytokines. Concentration was calculated via a standard 
curve of the corresponding recombinant cytokine. 
 
Results summarized in Article (IV), Fig. 1 showed that four extracts belonging 
to macroalgae Caulerpa racemosa, Chaetomorpha aerea, Cystoseira crinita 
(reproductive) and Dilophus fasciola, exhibited the most promising anti-
inflammatory activity for both astrocyte and Class-II microglial activation. It 
has been shown in similar studies that C. racemosa possess anti-
inflammatory activity [176].  

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These results encourage the continuation of anti-inflammatory studies of 
these extracts, to define whether they might provide new agents for the 
treatment of inflammatory diseases. 
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6. Conclusions and Future Considerations 

Marine natural products possess a tremendous chemical and pharmacological 
potential for drug discovery and development. Marine organisms have existed 
for more than 3.5 billion years. Throughout human history, they have been 
mainly seen as a source of food by the populations that were living near seas, 
rivers or lakes. However, with the advent of modern science, their significant 
research potential have been realized. Nowadays, marine organisms have 
been studied in several fields such as ecology, biology, chemistry and 
pharmacology. 
 
The aim of this thesis was to investigate the biological activity, i.e. 
antimicrobial and antiproliferative activities of extracts and synthetic 
compounds derived from marine resources. Study (I) and (II) showed that 
alkaloids clathrodin and oroidin could be considered as important scaffolds for 
the design of new drug candidates. In Study (I), where pyrrole-2-
aminoimidazole alkaloids clathrodin and oroidin, and synthetic analogs were 
prepared, it was possible to conclude that two indole-based derivatives 
showed promising results with MIC50 between 7 μM and 8 μM against Gram-
positive bacteria (Enterococcus faecalis and Staphylococcus aureus). 
However, these same derivatives presented low IC50, when tested against 
Huh-7 hepatocyte-derived cellular carcinoma cell line. Selectivity index, an 
important and widely used parameter, was also applied to evaluate the 
compounds as antimicrobial agents (eukaryotic vs prokaryotic cells). A 5-
chloro-indole derivative and a 4-phenyl-2-aminoimidazole derivative displayed 
values higher than 8, showing a greater specificity for prokaryotic cells. In 
Study (II), where clathrodin was used as an inspirational structure for the 
synthesis of new benzimidazole and 2-aminobenzothiazole analogs, a 
derivative of 2-aminobenzothiazole was found to display the best activity with 
an IC50 of 16 μM against an human melanoma cell line and IC50 of 71 μM 
against a non-cancerous, embryonic mouse fibroblast cell line, showing a 
moderate selectivity towards cancerous cells (SI = 4).  
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Study (III) showed the importance of a marine natural product scaffold for the 
design of new molecules. In this case, okadaic acid was used as an 
inspiration for the synthesis of crown ether acyl derivatives. A macrocycle 
derivative demonstrated to be the most active with MIC50 of 7.2 μM and 38.5 
μM against bacteria S. aureus and fungus C. albicans.  
 
Finally, Study (IV) showed the importance of marine bioprospecting in the 
Aegean Sea. Cyanobacteria, micro- and macroalgae specimens were 
collected and several bioassays were carried out. Extracts derived from a 
diatom, Amphora cf capitellata, showed antimicrobial effects at 100 μg/mL, 
i.e. full growth inhibition of Candida albicans, and inhibitions in the order of 
68% and 83% of Gram-positive E. faecalis and S. aureus.  
 
With the results of the existing studies, a lot of future work can be developed: 
optimizing the existing synthetic compound structures, fractionating the active 
extracts studied and performing new bioactivity assays and structure-activity 
relationship analyses. 
 
 
6.1. Future research 

The results of this thesis showed that some of the samples studied have 
potential, in the future, to become candidates for generating new 
pharmaceuticals, nutraceuticals or cosmeceuticals. As future research, a 
number of ideas can be considered: 
• screening with more resistant strains: in the past decades, microbes, 
especially bacteria, have developed cross-resistance to a series of 
structurally and functionally unrelated drugs, making multidrug 
resistance one of the most alarming threats to human health. The 
combination of a marine-derived compound and other drugs could 
provide a novel insight to combat multidrug resistance; 
• on-line combination of bioassays with chemical and structural 
characterization: although challenging, this strategy could allow for a 

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rapid and simultaneous screening, and identification of bioactive 
compounds with several biological activities (for example, the ones 
presented in Study (IV)) in matrices with no prior purification steps. 
However, it would require significant time and effort to establish an 
assay amenable for this type of samples; 
• study of the mode of action: this task would be challenging as well, but 
critical for understanding the principles of the bioactive compound 
uptake, metabolism of a cell exposed to a compound and identifying the 
molecular target sites of the compound. The goal of this study would be 
to understand the action of compounds in its entirety. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 










71 
References 
 
[1] T. O. Larsen, J. Smedsgaard, K. F. Nielsen, M. E. Hansen, and J. C. Frisvad, 
“Phenotypic taxonomy and metabolite profiling in microbial drug discovery”, Nat. Prod. 
Rep., vol. 22, no. 6, p. 672, Dec. 2005. 
[2] A. Kossel, Ueber die chemische Zusammensetzung der Zelle [The chemical 
composition of the cell]. Archiv für Physiologie, 1891. 
[3] G. M. König, A. D. Wright, O. Sticher, C. K. Angerhofer, and J. M. Pezzuto, “Biological 
activities of selected marine natural products”, Planta Med., vol. 60, no. 6, pp. 532–7, 
Dec. 1994. 
[4] W. Bergmann and R. J. Feeney, “Contributions to the study of marine products. XXXII. 
The nucleosides of sponges”, J. Org. Chem., vol. 16, pp. 981–987, 1951. 
[5] W. Bergmann and D. C. Burke, “Contributions to the Study of Marine Products. XL. 
The Nucleosides of Sponges. 1 IV. Spongosine 2”, J. Org. Chem., vol. 21, no. 2, pp. 
226–228, Feb. 1956. 
[6] W. Bergmann and M. F. Stempien, “Contributions to the Study of Marine Products. 
XLIII. The Nucleosides of Sponges. V. The Synthesis of Spongosine 1”, J. Org. 
Chem., vol. 22, no. 12, pp. 1575–1577, Dec. 1957. 
[7] L. Zhang, R. An, J. Wang, N. Sun, S. Zhang, J. Hu, and J. Kuai, “Exploring novel 
bioactive compounds from marine microbes”, Curr. Opin. Microbiol., vol. 8, no. 3, pp. 
276–81, Jun. 2005. 
[8] A. J. Weinheimer and R. L. Spraggins, “The occurrence of two new prostaglandin 
derivatives (15-epi-PGA2 and its acetate, methyl ester) in the Gorgonian Chemistry of 
Coelenterates. XV”, Tetrahedron Lett., vol. 10, no. 59, pp. 5185–5188, Jan. 1969. 
[9] A. M. S. Mayer, A. D. Rodríguez, O. Taglialatela-Scafati, and N. Fusetani, “Marine 
pharmacology in 2009-2011: marine compounds with antibacterial, antidiabetic, 
antifungal, anti-inflammatory, antiprotozoal, antituberculosis, and antiviral activities; 
affecting the immune and nervous systems, and other miscellaneous mechanisms of 
action“, Mar. Drugs, vol. 11, no. 7, pp. 2510–73, Jul. 2013. 
[10] B. B. Mishra and V. K. Tiwari, “Natural products: an evolving role in future drug 
discovery”, Eur. J. Med. Chem., vol. 46, no. 10, pp. 4769–807, Oct. 2011. 
[11] T. F. Molinski, D. S. Dalisay, S. L. Lievens, and J. P. Saludes, “Drug development 
from marine natural products”, Nat. Rev. Drug Discov., vol. 8, no. 1, pp. 69–85, Jan. 
2009. 

72 
[12] M. Schumacher, M. Kelkel, M. Dicato, and M. Diederich, “Gold from the sea: marine 
compounds as inhibitors of the hallmarks of cancer”, Biotechnol. Adv., vol. 29, no. 5, 
pp. 531–47, Jan. 2011. 
[13] A. Kijjoa and P. Sawangwong, “Drugs and Cosmetics from the Sea”, Mar. Drugs, vol. 
2, no. 2, pp. 73–82, May 2004. 
[14] S.-K. Lin, “Marine Nutraceuticals: Prospects and Perspectives”. By Se-Kwon Kim, 
CRC Press, 2013; 464 Pages. Price £108.00, ISBN 978-1-4665-1351-8”, Mar. Drugs, 
vol. 11, no. 4, pp. 1300–1303, Apr. 2013. 
[15] J. Peng, X. Shen, K. A. El Sayed, D. C. Dunbar, T. L. Perry, S. P. Wilkins, M. T. 
Hamann, S. Bobzin, J. Huesing, R. Camp, M. Prinsen, D. Krupa, and M. A. Wideman, 
“Marine Natural Products as Prototype Agrochemical Agents”, J. Agric. Food Chem., 
vol. 51, no. 8, pp. 2246–2252, Apr. 2003. 
[16] J. W. Blunt, B. R. Copp, M. H. G. Munro, P. T. Northcote, and M. R. Prinsep, “Marine 
natural products”, Nat. Prod. Rep., vol. 28, no. 2, pp. 196–268, Mar. 2011. 
[17] J. W. Blunt, B. R. Copp, R. A. Keyzers, M. H. G. Munro, and M. R. Prinsep, “Marine 
natural products”, Nat. Prod. Rep., vol. 31, no. 2, pp. 160–258, Jan. 2014. 
[18] J. W. Blunt, B. R. Copp, R. A. Keyzers, M. H. G. Munro, and M. R. Prinsep, “Marine 
natural products”, Nat. Prod. Rep., vol. 30, no. 2, pp. 237–323, Feb. 2013. 
[19] J. W. Blunt, B. R. Copp, R. A. Keyzers, M. H. G. Munro, and M. R. Prinsep, “Marine 
natural products”, Nat. Prod. Rep., vol. 32, no. 2, pp. 116–211, Jan. 2015. 
[20] W. H. Gerwick and B. S. Moore, “Lessons from the past and charting the future of 
marine natural products drug discovery and chemical biology”, Chem. Biol., vol. 19, 
no. 1, pp. 85–98, Jan. 2012. 
[21] R. T. Hill and W. Fenical, “Pharmaceuticals from marine natural products: surge or 
ebb?”, Curr. Opin. Biotechnol., vol. 21, no. 6, pp. 777–9, Dec. 2010. 
[22] E. Roskov Y., Abucay L., Orrell T., Nicolson D., Kunze T., Flann C., Bailly N., Kirk P., 
Bourgoin T., DeWalt R.E., Decock W., De Wever A., “Species 2000 & ITIS Catalogue 
of Life”, Naturalis, Leiden, the Netherlands. [Online]. Available: 
http://www.catalogueoflife.org/. [Accessed: 17-Oct-2015]. 
[23] J. M. Arrieta, S. Arnaud-Haond, and C. M. Duarte, “What lies underneath: conserving 
the oceans’ genetic resources”, Proc. Natl. Acad. Sci. U. S. A., vol. 107, no. 43, pp. 
18318–24, Oct. 2010. 
[24] M. F. de Jesus Raposo, R. M. S. C. de Morais, and A. M. M. B. de Morais, “Health 
applications of bioactive compounds from marine microalgae”, Life Sci., vol. 93, no. 

73 
15, pp. 479–86, Oct. 2013. 
[25] T. M. Mata, A. A. Martins, and N. S. Caetano, “Microalgae for biodiesel production and 
other applications: A review”, Renew. Sustain. Energy Rev., vol. 14, no. 1, pp. 217–
232, Jan. 2010. 
[26] R. Contreras, J. Paniagua-Michel, and J. Olmos, “Chapter 3 - Identification of 
Microalgae Producers of Commercially Important Compounds”, in Marine Algae 
Extracts: Processes, Products, and Applications, Volume 2, First., S.-K. Kim and K. 
Chojnacka, Eds. Wiley-VCH, 2015, pp. 41–58. 
[27] M. Plaza, M. Herrero, A. Cifuentes, and E. Ibáñez, “Innovative natural functional 
ingredients from microalgae”, J. Agric. Food Chem., vol. 57, no. 16, pp. 7159–70, Aug. 
2009. 
[28] K. H. Cha, S. W. Kang, C. Y. Kim, B. H. Um, Y. R. Na, and C.-H. Pan, “Effect of 
pressurized liquids on extraction of antioxidants from Chlorella vulgaris”, J. Agric. Food 
Chem., vol. 58, no. 8, pp. 4756–61, Apr. 2010. 
[29] R. Pratt, J. F. Oneto, and J. Pratt, “Studies on Chlorella vulgaris. X. Influence of the 
Age of the Culture on the Accumulation of Chlorellin”, Am. J. Bot., vol. 32, no. 7, pp. 
405–408, Jul. 1945. 
[30] J. V. Costa and M. G. de Morais, “Microalgae for Food Production”, in Fermentation 
Processes Engineering in the Food Industry, C. R. Soccol, A. Pandey, and C. 
Larroche, Eds. CRC Press, 2013, pp. 405–428. 
[31] A. Hosseini Tafreshi and M. Shariati, “Dunaliella biotechnology: methods and 
applications”, J. Appl. Microbiol., vol. 107, no. 1, pp. 14–35, Jul. 2009. 
[32] K. N. Chidambara Murthy, A. Vanitha, J. Rajesha, M. Mahadeva Swamy, P. R. 
Sowmya, and G. A. Ravishankar, “In vivo antioxidant activity of carotenoids from 
Dunaliella salina ‒ a green microalga”, Life Sci., vol. 76, no. 12, pp. 1381–90, Feb. 
2005. 
[33] J. W. Schopf, “Microfossils of the Early Archean Apex Chert: New Evidence of the 
Antiquity of Life”, Science, vol. 260, no. 5108, pp. 640–646, Apr. 1993. 
[34] W. Altermann and J. Kazmierczak, “Archean microfossils: a reappraisal of early life on 
Earth”, Res. Microbiol., vol. 154, no. 9, pp. 611–7, Nov. 2003. 
[35] B. Rasmussen, I. R. Fletcher, J. J. Brocks, and M. R. Kilburn, “Reassessing the first 
appearance of eukaryotes and cyanobacteria”, Nature, vol. 455, no. 7216, pp. 1101–4, 
Oct. 2008. 
[36] A. M. Burja, B. Banaigs, E. Abou-Mansour, J. Grant Burgess, and P. C. Wright, 

74 
“Marine cyanobacteria—a prolific source of natural products”, Tetrahedron, vol. 57, no. 
46, pp. 9347–9377, Nov. 2001. 
[37] M. T. Runnegar, S. M. Kong, Y. Z. Zhong, J. L. Ge, and S. C. Lu, “The role of 
glutathione in the toxicity of a novel cyanobacterial alkaloid cylindrospermopsin in 
cultured rat hepatocytes”, Biochem. Biophys. Res. Commun., vol. 201, no. 1, pp. 235–
41, May 1994. 
[38] M. L. Saker and G. K. Eaglesham, “The accumulation of cylindrospermopsin from the 
cyanobacterium Cylindrospermopsis raciborskii in tissues of the Redclaw crayfish 
Cherax quadricarinatus”, Toxicon, vol. 37, no. 7, pp. 1065–77, Jul. 1999. 
[39] M. Gutiérrez, T. L. Suyama, N. Engene, J. S. Wingerd, T. Matainaho, and W. H. 
Gerwick, “Apratoxin D, a Potent Cytotoxic Cyclodepsipeptide from Papua New Guinea 
Collections of the Marine Cyanobacteria Lyngbya majuscula and Lyngbya sordida”, J. 
Nat. Prod., vol. 71, no. 6, pp. 1099–1103, Jun. 2008. 
[40] F. D. Horgen, W. Y. Yoshida, and P. J. Scheuer, “Malevamides A-C, new 
depsipeptides from the marine cyanobacterium Symploca laeteviridis”, J. Nat. Prod., 
vol. 63, no. 4, pp. 461–7, Apr. 2000. 
[41] R. A. Medina, D. E. Goeger, P. Hills, S. L. Mooberry, N. Huang, L. I. Romero, E. 
Ortega-Barría, W. H. Gerwick, and K. L. McPhail, "Coibamide A, a Potent 
Antiproliferative Cyclic Depsipeptide from the Panamanian Marine Cyanobacterium 
Leptolyngbya sp”, J. Am. Chem. Soc., vol. 130, no. 20, pp. 6324–6325, May 2008. 
[42] L. T. Tan, “Bioactive natural products from marine cyanobacteria for drug discovery”, 
Phytochemistry, vol. 68, no. 7, pp. 954–79, Apr. 2007. 
[43] M. L. Hillwig, Q. Zhu, and X. Liu, “Biosynthesis of Ambiguine Indole Alkaloids in 
Cyanobacterium Fischerella ambigua”, ACS Chem. Biol., vol. 9, no. 2, pp. 372–377, 
Feb. 2014. 
[44] M. L. Micallef, D. Sharma, B. M. Bunn, L. Gerwick, R. Viswanathan, and M. C. Moffitt, 
“Comparative analysis of hapalindole, ambiguine and welwitindolinone gene clusters 
and reconstitution of indole-isonitrile biosynthesis from cyanobacteria”, BMC 
Microbiol., vol. 14, no. 1, p. 213, Jan. 2014. 
[45] K. Stratmann, J. Belli, C. M. Jensen, R. E. Moore, and G. M. L. Patterson, 
“Aulosirazole, a novel solid tumor selective cytotoxin from the blue-green alga Aulosira 
fertilissima”, J. Org. Chem., vol. 59, no. 21, pp. 6279–6281, Oct. 1994. 
[46] G. V Subbaraju, T. Golakoti, G. M. Patterson, and R. E. Moore, “Three new 
cryptophycins from Nostoc sp. GSV 224”, J. Nat. Prod., vol. 60, no. 3, pp. 302–5, Mar. 
1997. 

75 
[47] G. Trimurtulu, I. Ohtani, G. M. L. Patterson, R. E. Moore, T. H. Corbett, F. A. Valeriote, 
and L. Demchik, “Total Structures of Cryptophycins, Potent Antitumor Depsipeptides 
from the Blue-Green Alga Nostoc sp. Strain GSV 224”, J. Am. Chem. Soc., vol. 116, 
no. 11, pp. 4729–4737, Jun. 1994. 
[48] K. L. Rinehart, “Antitumor compounds from tunicates”, Med. Res. Rev., vol. 20, no. 1, 
pp. 1–27, Jan. 2000. 
[49] H. Sone, H. Kigoshi, and K. Yamada, “Isolation and stereostructure of dolastatin I, a 
cytotoxic cyclic hexapeptide from the Japanese sea hare Dolabella auricularia”, 
Tetrahedron, vol. 53, no. 24, pp. 8149–8154, Jun. 1997. 
[50] H. Wang, K. Sivonen, L. Rouhiainen, D. P. Fewer, C. Lyra, A. Rantala-Ylinen, J. 
Vestola, J. Jokela, K. Rantasärkkä, Z. Li, and B. Liu, “Genome-derived insights into 
the biology of the hepatotoxic bloom-forming cyanobacterium Anabaena sp. strain 90”, 
BMC Genomics, vol. 13, no. 1, p. 613, 2012. 
[51] M. Kadhasamy and K. D. Arunachalam, “Evaluation of in vitro antibacterial property of 
seaweeds of southeast coast of India”, African Journal of Biotechnology, vol. 7, no. 12. 
Academic Journals, pp. 1958–1961, 17-Jun-2008. 
[52] G. Pierre, V. Sopena, C. Juin, A. Mastouri, M. Graber, and T. Maugard, “Antibacterial 
activity of a sulfated galactan extracted from the marine alga Chaetomorpha aerea 
against Staphylococcus aureus”, Biotechnol. Bioprocess Eng., vol. 16, no. 5, pp. 937–
945, Sep. 2011. 
[53] A. González del Val, G. Platas, A. Basilio, A. Cabello, J. Gorrochategui, I. Suay, F. 
Vicente, E. Portillo, M. Jiménez del Río, G. G. Reina, and F. Peláez, “Screening of 
antimicrobial activities in red, green and brown macroalgae from Gran Canaria 
(Canary Islands, Spain)”, Int. Microbiol., vol. 4, no. 1, pp. 35–40, Mar. 2001. 
[54] L. Mhadhebi, A. Mhadhebi, J. Robert, and A. Bouraoui, “Antioxidant, Anti-inflammatory 
and Antiproliferative Effects of Aqueous Extracts of Three Mediterranean Brown 
Seaweeds of the Genus Cystoseira”, Iran. J. Pharm. Res.  IJPR, vol. 13, no. 1, pp. 
207–20, Jan. 2014. 
[55] C. S. Vairappan, T. Kawamoto, H. Miwa, and M. Suzuki, “Potent antibacterial activity 
of halogenated compounds against antibiotic-resistant bacteria”, Planta Med., vol. 70, 
no. 11, pp. 1087–90, Nov. 2004. 
[56] K.-B. Oh, J. H. Lee, S.-C. Chung, J. Shin, H. J. Shin, H.-K. Kim, and H.-S. Lee, 
“Antimicrobial activities of the bromophenols from the red alga Odonthalia corymbifera 
and some synthetic derivatives”, Bioorg. Med. Chem. Lett., vol. 18, no. 1, pp. 104–8, 
Jan. 2008. 

76 
[57] T. Kuda, T. Kunii, H. Goto, T. Suzuki, and T. Yano, “Varieties of antioxidant and 
antibacterial properties of Ecklonia stolonifera and Ecklonia kurome products 
harvested and processed in the Noto peninsula, Japan”, Food Chem., vol. 103, no. 3, 
pp. 900–905, Jan. 2007. 
[58] G. D. Love, E. Grosjean, C. Stalvies, D. A. Fike, J. P. Grotzinger, A. S. Bradley, A. E. 
Kelly, M. Bhatia, W. Meredith, C. E. Snape, S. A. Bowring, D. J. Condon, and R. E. 
Summons, “Fossil steroids record the appearance of Demospongiae during the 
Cryogenian period”, Nature, vol. 457, no. 7230, pp. 718–21, Feb. 2009. 
[59] D. B. Mills, L. M. Ward, C. Jones, B. Sweeten, M. Forth, A. H. Treusch, and D. E. 
Canfield, “Oxygen requirements of the earliest animals”, Proc. Natl. Acad. Sci. U. S. 
A., vol. 111, no. 11, pp. 4168–72, Mar. 2014. 
[60] E. H. Belarbi, A. Contreras Gómez, Y. Chisti, F. García Camacho, and E. Molina 
Grima, “Producing drugs from marine sponges”, Biotechnol. Adv., vol. 21, no. 7, pp. 
585–98, Oct. 2003. 
[61] B. Haefner, “Drugs from the deep: Marine natural products as drug candidates”, Drug 
Discovery Today, vol. 8. pp. 536–544, 2003. 
[62] D. Sipkema, M. C. R. Franssen, R. Osinga, J. Tramper, and R. H. Wijffels, “Marine 
sponges as pharmacy”, Mar. Biotechnol. (NY)., vol. 7, no. 3, pp. 142–62, Jan. 2005. 
[63] S. Shen, D. Liu, C. Wei, P. Proksch, and W. Lin, “Purpuroines A–J, halogenated 
alkaloids from the sponge Iotrochota purpurea with antibiotic activity and regulation of 
tyrosine kinases”, Bioorg. Med. Chem., vol. 20, no. 24, pp. 6924–6928, Dec. 2012. 
[64] H. Yamazaki, D. S. Wewengkang, S.-I. Kanno, M. Ishikawa, H. Rotinsulu, R. E. P. 
Mangindaan, and M. Namikoshi, “Papuamine and haliclonadiamine, obtained from an 
Indonesian sponge Haliclona sp., inhibited cell proliferation of human cancer cell 
lines”, Nat. Prod. Res., vol. 27, no. 11, pp. 1012–5, Jan. 2013. 
[65] A. L. Waters, R. T. Hill, A. R. Place, and M. T. Hamann, “The expanding role of marine 
microbes in pharmaceutical development”, Curr. Opin. Biotechnol., vol. 21, no. 6, pp. 
780–786, Dec. 2010. 
[66] S. S. Ebada, W. Lin, and P. Proksch, “Bioactive Sesterterpenes and Triterpenes from 
Marine Sponges: Occurrence and Pharmacological Significance”, Mar. Drugs, vol. 8, 
no. 2, pp. 313–346, Feb. 2010. 
[67] G.-M. Suarez-Jimenez, A. Burgos-Hernandez, and J.-M. Ezquerra-Brauer, “Bioactive 
Peptides and Depsipeptides with Anticancer Potential: Sources from Marine Animals”, 
Mar. Drugs, vol. 10, no. 12, pp. 963–986, Apr. 2012. 

77 
[68] A. Araki, M. Tsuda, T. Kubota, Y. Mikami, J. Fromont, and J. Kobayashi, “Nagelamide 
J, a Novel Dimeric Bromopyrrole Alkaloid from a Sponge Agelas Species”, Org. Lett., 
vol. 9, no. 12, pp. 2369–2371, Jun. 2007. 
[69] G. R. Pettit, Z. A. Chicacz, F. Gao, C. L. Herald, M. R. Boyd, J. M. Schmidt, and J. N. 
A. Hooper, “Antineoplastic agents. 257. Isolation and structure of spongistatin 1”, J. 
Org. Chem., vol. 58, no. 6, pp. 1302–1304, Mar. 1993. 
[70] K. von Schwarzenberg and A. M. Vollmar, “Targeting apoptosis pathways by natural 
compounds in cancer: Marine compounds as lead structures and chemical tools for 
cancer therapy”, Cancer Lett., vol. 332, no. 2, pp. 295–303, May 2013. 
[71] C. B. Buck, C. D. Thompson, J. N. Roberts, M. Müller, D. R. Lowy, and J. T. Schiller, 
“Carrageenan is a potent inhibitor of papillomavirus infection”, PLoS Pathog., vol. 2, 
no. 7, p. e69, Jul. 2006. 
[72] M. F. de Jesus Raposo, A. M. B. de Morais, and R. M. S. C. de Morais, “Marine 
Polysaccharides from Algae with Potential Biomedical Applications”, Mar. Drugs, vol. 
13, no. 5, pp. 2967–3028, Jan. 2015. 
[73] R. K. Devappa, H. P. S. Makkar, and K. Becker, “Jatropha Diterpenes: a Review”, J. 
Am. Oil Chem. Soc., vol. 88, no. 3, pp. 301–322, Dec. 2010. 
[74] M. Kladi, H. Xenaki, C. Vagias, P. Papazafiri, and V. Roussis, “New cytotoxic 
sesquiterpenes from the red algae Laurencia obtusa and Laurencia microcladia”, 
Tetrahedron, vol. 62, no. 1, pp. 182–189, Jan. 2006. 
[75] S.-K. Kim and I. Wijesekara, “Development and biological activities of marine-derived 
bioactive peptides: A review”, J. Funct. Foods, vol. 2, no. 1, pp. 1–9, Jan. 2010. 
[76] P. A. Harnedy and R. J. FitzGerald, “Bioactive proteins, peptides, and amino acids 
from macroalgae”, J. Phycol., vol. 47, no. 2, pp. 218–232, Apr. 2011. 
[77] D.-H. Ngo, T.-S. Vo, D.-N. Ngo, I. Wijesekara, and S.-K. Kim, “Biological activities and 
potential health benefits of bioactive peptides derived from marine organisms”, Int. J. 
Biol. Macromol., vol. 51, no. 4, pp. 378–83, Nov. 2012. 
[78] S. Matsunaga, N. Fusetani, and S. Konosu, “Bioactive Marine Metabolites, IV. 
Isolation and the Amino Acid Composition of Discodermin A, an Antimicrobial Peptide, 
from the Marine Sponge Discodermia kiiensis”, J. Nat. Prod., vol. 48, no. 2, pp. 236–
241, Mar. 1985. 
[79] K. C. Güven, A. Percot, and E. Sezik, “Alkaloids in marine algae”, Mar. Drugs, vol. 8, 
no. 2, pp. 269–84, Jan. 2010. 
[80] N. Netz and T. Opatz, “Marine Indole Alkaloids”, Mar. Drugs, vol. 13, no. 8, pp. 4814–

78 
4915, Aug. 2015. 
[81] S. W. Pelletier, The nature and definition of an alkaloid, Alkaloids: New York, NY, 
USA: John Wiley & Sons, 1983. 
[82] D. Kumar and D. S. Rawat, “Opportunity, Challenge and Scope of Natural Products in 
Medicinal Chemistry”, V. K. Tiwari and B. B. Mishra, Eds. New Delhi, 2011, pp. 213–
268. 
[83] S. Forenza, L. Minale, R. Riccio, and E. Fattorusso, “New bromo-pyrrole derivatives 
from the sponge Agelas oroides”, J. Chem. Soc. D Chem. Commun., no. 18, p. 1129, 
Jan. 1971. 
[84] T. Endo, M. Tsuda, T. Okada, S. Mitsuhashi, H. Shima, K. Kikuchi, Y. Mikami, J. 
Fromont, and J. Kobayashi, “Nagelamides A-H, new dimeric bromopyrrole alkaloids 
from marine sponge Agelas species”, J. Nat. Prod., vol. 67, no. 8, pp. 1262–7, Aug. 
2004. 
[85] C. Cuevas and A. Francesch, “Development of Yondelis (trabectedin, ET-743). A 
semisynthetic process solves the supply problem”, Nat. Prod. Rep., vol. 26, no. 3, pp. 
322–37, Mar. 2009. 
[86] Q. Xu, K.-C. Huang, K. Tendyke, J. Marsh, J. Liu, D. Qiu, B. A. Littlefield, K. Nomoto, 
O. Atasoylu, C. A. Risatti, J. B. Sperry, and A. B. Smith, “In vitro and in vivo anticancer 
activity of (+)-spongistatin 1”, Anticancer Res., vol. 31, no. 9, pp. 2773–9, Sep. 2011. 
[87] K. Trisuwan, V. Rukachaisirikul, Y. Sukpondma, S. Phongpaichit, S. Preedanon, and 
J. Sakayaroj, “Lactone derivatives from the marine-derived fungus Penicillium sp. 
PSU-F44”, Chem. Pharm. Bull. (Tokyo)., vol. 57, no. 10, pp. 1100–2, Oct. 2009. 
[88] A. Mishra, K. Kavita, and B. Jha, “Characterization of extracellular polymeric 
substances produced by microalgae Dunaliella salina”, Carbohydr. Polym., vol. 83, no. 
2, pp. 852–857, Jan. 2011. 
[89] D. J. Newman and G. M. Cragg, “Natural products as sources of new drugs over the 
30 years from 1981 to 2010”, J. Nat. Prod., vol. 75, no. 3, pp. 311–35, Mar. 2012. 
[90] F. von Nussbaum, M. Brands, B. Hinzen, S. Weigand, and D. Häbich, “Antibacterial 
natural products in medicinal chemistry ‒ exodus or revival?”, Angew. Chem. Int. Ed. 
Engl., vol. 45, no. 31, pp. 5072–129, Aug. 2006. 
[91] D.-X. Kong, Y.-Y. Jiang, and H.-Y. Zhang, “Marine natural products as sources of 
novel scaffolds: achievement and concern”, Drug Discov. Today, vol. 15, no. 21–22, 
pp. 884–886, Nov. 2010. 
[92] D. Uemura, K. Takahashi, T. Yamamoto, C. Katayama, J. Tanaka, Y. Okumura, and 

79 
Y. Hirata, “Norhalichondrin A: an antitumor polyether macrolide from a marine 
sponge”, J. Am. Chem. Soc., vol. 107, no. 16, pp. 4796–4798, Aug. 1985. 
[93] Y. Hirata and D. Uemura, “Halichondrins - antitumor polyether macrolides from a 
marine sponge”, Pure Appl. Chem., vol. 58, no. 5, pp. 701–710, Jan. 1986. 
[94] T. D. Aicher, K. R. Buszek, F. G. Fang, C. J. Forsyth, S. H. Jung, Y. Kishi, M. C. 
Matelich, P. M. Scola, D. M. Spero, and S. K. Yoon, “Total synthesis of halichondrin B 
and norhalichondrin B”, J. Am. Chem. Soc., vol. 114, no. 8, pp. 3162–3164, Apr. 1992. 
[95] Y.-W. Chin, M. J. Balunas, H. B. Chai, and A. D. Kinghorn, “Drug discovery from 
natural sources”, AAPS J., vol. 8, no. 2, pp. E239–53, Jan. 2006. 
[96] P. A. Wender, B. A. Dechristopher, and A. J. Schrier, “Efficient synthetic access to a 
new family of highly potent bryostatin analogues via a Prins-driven macrocyclization 
strategy”, J. Am. Chem. Soc., vol. 130, no. 21, pp. 6658–9, May 2008. 
[97] B. Dhorajiya, M. Malani, and B. Dholakiya, “Extraction and Preservation Protocol of 
Anti-Cancer Agents from Marine World”, Chem. Sci. J., vol. 2, no. 32, 2012. 
[98] M. D. Hilton, “Natural products: Discovery and screening”, in Handbook of Industrial 
Cell Cultures, V. A. Vinci and S. R. Parekh, Eds. Humana, Totowa, NK, 2003, pp. 
107–136. 
[99] C. I. L. Justino, K. Duarte, and A. C. Freitas, “Chapter 3 - Classical Methodologies for 
Preparation of Extracts and Fractions”, in Analysis of Marine Samples in Search of 
Bioactive Compounds, First., vol. 65, T. Rocha-Santos and A. C. Duarte, Eds. 
Elsevier, 2014, pp. 35–57. 
[100] L. Najafian and A. S. Babji, “A review of fish-derived antioxidant and antimicrobial 
peptides: their production, assessment, and applications”, Peptides, vol. 33, no. 1, pp. 
178–85, Jan. 2012. 
[101] K. Duarte, T. A. P. Rocha-Santos, A. C. Freitas, and A. C. Duarte, “Analytical 
techniques for discovery of bioactive compounds from marine fungi”, TrAC Trends 
Anal. Chem., vol. 34, pp. 97–110, Apr. 2012. 
[102] S. M. Kupchan, R. W. Britton, J. A. Lacadie, M. F. Ziegler, and C. W. Sigel, “Tumor 
inhibitors. 100. Isolation and structural elucidation of bruceantin and bruceantinol, new 
potent antileukemic quassinoids from Brucea antidysenterica”, J. Org. Chem., vol. 40, 
no. 5, pp. 648–654, Mar. 1975. 
[103] G. S. Sittampalam, N. P. Coussens, H. Nelson, M. Arkin, D. Auld, C. Austin, B. Bejcek, 
M. Glicksman, J. Inglese, P. W. Iversen, Z. Li, J. McGee, O. McManus, L. Minor, A. 
Napper, J. M. Peltier, T. Riss, J. O. Joseph Trask, and J. Weidner, “Assay Guidance 

80 
Manual.” Eli Lilly & Company and the National Center for Advancing Translational 
Sciences, 2004. 
[104] S. I. G. H. M. Montalvão, V. Singh, and S. Haque, “Chapter 5 - Bioassays for 
bioactivity screening”, in Analysis of Marine Samples in Search of Bioactive 
Compounds, First., vol. 65, T. Rocha-Santos and A. C. Duarte, Eds. Elsevier, 2014, 
pp. 79–114. 
[105] S. Leston, M. Nunes, J. Rosa, M. F. L. Lemos, F. Ramos, and M. A. Pardal, “Chapter 
2 - Prospection, Collection, and Preservation of Marine Samples”, in Analysis of 
Marine Samples in Search of Bioactive Compounds, First., vol. 65, T. Rocha-Santos 
and A. C. Duarte, Eds. Elsevier, 2014, pp. 15–34. 
[106] A. Martins, H. Vieira, H. Gaspar, and S. Santos, “Marketed marine natural products in 
the pharmaceutical and cosmeceutical industries: tips for success”, Mar. Drugs, vol. 
12, no. 2, pp. 1066–101, Mar. 2014. 
[107] EMA, “EMA - European Medicines Agency.” [Online]. Available: 
http://www.ema.europa.eu/. [Accessed: 19-Nov-2015]. 
[108] FDA, “FDA - U.S. Food and Drug Administration.” [Online]. Available: 
http://www.fda.gov. [Accessed: 19-Nov-2015]. 
[109] American Association for Cancer Research, “AACR Cancer progress report”, Clin 
Cancer Res, vol. 18 (suppl. 1), 2012. 
[110] R. Chin and B. Y. Lee, Principles and Practice of Clinical Trial Medicine. Elsevier, 
2008. 
[111] I. Kola and J. Landis, “Can the pharmaceutical industry reduce attrition rates?”, Nat. 
Rev. Drug Discov., vol. 3, no. 8, pp. 711–5, Aug. 2004. 
[112] Institute of Medicine. "Ethical and Scientific Issues in Studying the Safety of Approved 
Drugs", The National Academies Press, 2012. 
[113] M. M. Mello, S. N. Goodman, and R. R. Faden, “Ethical considerations in studying 
drug safety - The Institute of Medicine report”, N. Engl. J. Med., vol. 367, no. 10, pp. 
959–64, Sep. 2012. 
[114] C. . Meyer, “Marine pharmacology”, The Global Marine Pharmaceuticals Pipeline. 
[Online]. Available: http://marinepharmacology.midwestern.edu/. [Accessed: 08-Oct-
2015]. 
[115] R. Montaser and H. Luesch, “Marine natural products: a new wave of drugs?”, Future 
Med. Chem., vol. 3, no. 12, pp. 1475–89, Sep. 2011. 
[116] H. R. Hendriks, H. H. Fiebig, R. Giavazzi, S. P. Langdon, J. M. Jimeno, and G. T. 

81 
Faircloth, “High antitumour activity of ET743 against human tumour xenografts from 
melanoma, non-small-cell lung and ovarian cancer”, Ann. Oncol., vol. 10, no. 10, pp. 
1233–40, Oct. 1999. 
[117] R. Garcia-Carbonero, J. G. Supko, J. Manola, M. V Seiden, D. Harmon, D. P. Ryan, 
M. T. Quigley, P. Merriam, J. Canniff, G. Goss, U. Matulonis, R. G. Maki, T. Lopez, T. 
A. Puchalski, M. A. Sancho, J. Gomez, C. Guzman, J. Jimeno, and G. D. Demetri, 
“Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive 
sarcomas of soft tissues refractory to chemotherapy”, 2004. 
[118] Y. Takebayashi, P. Pourquier, D. B. Zimonjic, K. Nakayama, S. Emmert, T. Ueda, Y. 
Urasaki, A. Kanzaki, S. I. Akiyama, N. Popescu, K. H. Kraemer, and Y. Pommier, 
“Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled 
nucleotide-excision repair”, Nat. Med., vol. 7, pp. 961–966, 2001. 
[119] P. M. Kris-Etherton, “Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and 
Cardiovascular Disease”, Circulation, vol. 106, no. 21, pp. 2747–2757, Nov. 2002. 
[120] K. He, “Accumulated Evidence on Fish Consumption and Coronary Heart Disease 
Mortality: A Meta-Analysis of Cohort Studies”, Circulation, vol. 109, no. 22, pp. 2705–
2711, Jun. 2004. 
[121] S. P. Whelton, J. He, P. K. Whelton, and P. Muntner, “Meta-analysis of observational 
studies on fish intake and coronary heart disease”, Am. J. Cardiol., vol. 93, no. 9, pp. 
1119–23, May 2004. 
[122] G. R. Pettit, Y. Kamano, C. L. Herald, Y. Fujii, H. Kizu, M. R. Boyd, F. E. Boettner, D. 
L. Doubek, J. M. Schmidt, J.-C. Chapuis, and C. Michel, “Isolation of dolastatins 10–15 
from the marine mollusc Dolabella auricularia”, Tetrahedron, vol. 49, no. 41, pp. 9151–
9170, Jan. 1993. 
[123] A. M. S. Mayer, “Marine Pharmacology Clinical Development”, 2015. [Online]. 
Available: http://marinepharmacology.midwestern.edu/clinPipeline.htm. [Accessed: 01-
Oct-2015]. 
[124] J. M. Vrolijk, A. Kaul, B. E. Hansen, V. Lohmann, B. L. Haagmans, S. W. Schalm, and 
R. Bartenschlager, “A replicon-based bioassay for the measurement of interferons in 
patients with chronic hepatitis C”, J. Virol. Methods, vol. 110, no. 2, pp. 201–9, Jun. 
2003. 
[125] R. W. Bauman, Microbiology with Diseases by Taxonomy, Third Edit. Pearson, 2010. 
[126] G. Kahlmeter, D. F. J. Brown, F. W. Goldstein, A. P. MacGowan, J. W. Mouton, I. 
Odenholt, A. Rodloff, C.-J. Soussy, M. Steinbakk, F. Soriano, and O. Stetsiouk, 
“European Committee on Antimicrobial Susceptibility Testing (EUCAST). Technical 

82 
Notes on antimicrobial susceptibility testing”, Clin. Microbiol. Infect., vol. 12, pp. 501–
503, 2006. 
[127] M. A. Wikler, F. R. Cockerill, W. A. Craig, M. N. Dudley, G. M. Eliopoulos, D. W. 
Hecht, J. F. Hindler, M. J. Ferraro, J. M. Swenson, D. E. Low, D. J. Sheehan, F. C. 
Tenover, J. D. Turnidge, M. P. Weinstein, and B. L. Zimmer, M02-A12: Performance 
Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Twelfth 
Edition, vol. M0–A12. 2015. 
[128] V. W. Rebecca, V. K. Sondak, and K. S. M. Smalley, “A brief history of melanoma: 
from mummies to mutations”, Melanoma Res., vol. 22, no. 2, pp. 114–22, Apr. 2012. 
[129] W. H. Organization, “GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and 
Prevalence Worldwide in 2012”, 2012. [Online]. Available: http://globocan.iarc.fr/. 
[Accessed: 12-Jul-2015]. 
[130] C. Garbe and U. Leiter, “Melanoma epidemiology and trends”, Clin. Dermatol., vol. 27, 
no. 1, pp. 3–9, Jan. 2009. 
[131] T. Regad, “Molecular and cellular pathogenesis of melanoma initiation and 
progression”, Cell. Mol. Life Sci., vol. 70, no. 21, pp. 4055–65, Nov. 2013. 
[132] M. R. Zaidi, C.-P. Day, and G. Merlino, “From UVs to metastases: modeling melanoma 
initiation and progression in the mouse”, J. Invest. Dermatol., vol. 128, no. 10, pp. 
2381–91, Oct. 2008. 
[133] S. P. M. Crouch, R. Kozlowski, K. J. Slater, and J. Fletcher, “The use of ATP 
bioluminescence as a measure of cell proliferation and cytotoxicity”, J. Immunol. 
Methods, vol. 160, no. 1, pp. 81–88, Jan. 1993. 
[134] T. Mosmann, “Rapid colorimetric assay for cellular growth and survival: application to 
proliferation and cytotoxicity assays”, J. Immunol. Methods, vol. 65, no. 1–2, pp. 55–
63, Dec. 1983. 
[135] D. I. Bounous, R. P. Campagnoli, and J. Brown, “Comparison of MTT colorimetric 
assay and tritiated thymidine uptake for lymphocyte proliferation assays using chicken 
splenocytes”, Avian Dis., vol. 36, no. 4, pp. 1022–7, Jan. 1992. 
[136] C. Korzeniewski and D. M. Callewaert, “An enzyme-release assay for natural 
cytotoxicity”, J. Immunol. Methods, vol. 64, no. 3, pp. 313–320, Nov. 1983. 
[137] D. B. Mitchell, K. S. Santone, and D. Acosta, “Evaluation of cytotoxicity in cultured 
cells by enzyme leakage”, J. Tissue Cult. Methods, vol. 6, no. 3–4, pp. 113–116, Sep. 
1980. 
[138] J. Zhang, T. Chung, and K. Oldenburg, “A Simple Statistical Parameter for Use in 

83 
Evaluation and Validation of High Throughput Screening Assays”, J. Biomol. Screen., 
vol. 4, no. 2, pp. 67–73, Jan. 1999. 
[139] S. Bollini, J. J. Herbst, G. T. Gaughan, T. A. Verdoorn, J. Ditta, G. M. Dubowchik, and 
A. Vinitsky, “High-throughput fluorescence polarization method for identification of 
FKBP12 ligands”, J. Biomol. Screen., vol. 7, no. 6, pp. 526–30, Dec. 2002. 
[140] E. A. Sergienko and S. Heynen-Genel, Diversity-Oriented Synthesis: Basics and 
Applications in Organic Synthesis, Drug Discovery, and Chemical Biology. John Wiley 
& Sons, 2013. 
[141] J. J. Richards, T. E. Ballard, and C. Melander, “Inhibition and dispersion of 
Pseudomonas aeruginosa biofilms with reverse amide 2-aminoimidazole oroidin 
analogues”, Org. Biomol. Chem., vol. 6, no. 8, pp. 1356–63, Apr. 2008. 
[142] J. J. Morales and A. D. Rodríguez, “The Structure of Clathrodin, a Novel Alkaloid 
Isolated from the Caribbean Sea Sponge Agelas clathrodes”, J. Nat. Prod., vol. 54, no. 
2, pp. 629–631, Mar. 1991. 
[143] R. Rosa, W. Silva, G. Escalona de Motta, A. D. Rodríguez, J. J. Morales, and M. Ortiz, 
“Anti-muscarinic activity of a family of C11N5 compounds isolated from Agelas 
sponges”, Experientia, vol. 48, no. 9, pp. 885–7, Sep. 1992. 
[144] A. Al-Sabi, J. McArthur, V. Ostroumov, and R. J. French, “Marine Toxins That Target 
Voltage-gated Sodium Channels”, Mar. Drugs, vol. 4, no. 3, pp. 157–192, Apr. 2006. 
[145] S. Peigneur, A. Zula, N. Zidar, F. Chan-Porter, R. Kirby, D. Madge, J. Ilaš, D. Kikelj, 
and J. Tytgat, “Action of clathrodin and analogues on voltage-gated sodium channels”, 
Mar. Drugs, vol. 12, no. 4, pp. 2132–43, Apr. 2014. 
[146] A. L. Rivera Rentas, R. Rosa, A. D. Rodríguez, and G. E. De Motta, “Effect of alkaloid 
toxins from tropical marine sponges on membrane sodium currents”, Toxicon, vol. 33, 
no. 4, pp. 491–497, Apr. 1995. 
[147] N. Zidar, Ž. Jakopin, D. J. Madge, F. Chan, J. Tytgat, S. Peigneur, M. S. Dolenc, T. 
Tomašić, J. Ilaš, L. P. Mašič, and D. Kikelj, “Substituted 4-phenyl-2-aminoimidazoles 
and 4-phenyl-4,5-dihydro-2-aminoimidazoles as voltage-gated sodium channel 
modulators”, Eur. J. Med. Chem., vol. 74, pp. 23–30, Mar. 2014. 
[148] S. Hammami, A. Bergaoui, N. Boughalleb, A. Romdhane, I. Khoja, M. Ben Halima 
Kamel, and Z. Mighri, “Antifungal effects of secondary metabolites isolated from 
marine organisms collected from the Tunisian coast”, Comptes Rendus Chim., vol. 13, 
no. 11, pp. 1397–1400, Nov. 2010. 
[149] F. Scala, E. Fattorusso, M. Menna, O. Taglialatela-Scafati, M. Tierney, M. Kaiser, and 

84 
D. Tasdemir, “Bromopyrrole alkaloids as lead compounds against protozoan 
parasites”, Mar. Drugs, vol. 8, no. 7, pp. 2162–74, Jan. 2010. 
[150] T. Tomašič, D. Nabergoj, S. Vrbek, N. Zidar, Ž. Jakopin, A. Žula, Ž. Hodnik, M. Jukič, 
M. Anderluh, J. Ilaš, M. S. Dolenc, J. Peluso, G. Ubeaud-Séquier, C. D. Muller, L. P. 
Mašič, and D. Kikelj, “Analogues of the marine alkaloids oroidin, clathrodin, and 
hymenidin induce apoptosis in human HepG2 and THP-1 cancer cells”, Med. Chem. 
Commun., vol. 6, no. 1, pp. 105–110, Jan. 2015. 
[151] R. V Shingalapur, K. M. Hosamani, and R. S. Keri, “Synthesis and evaluation of in 
vitro antimicrobial and antitubercular activity of 2-styryl benzimidazoles”, Eur. J. Med. 
Chem., vol. 44, no. 10, pp. 4244–8, Oct. 2009. 
[152] D. Zampieri, M. G. Mamolo, L. Vio, E. Banfi, G. Scialino, M. Fermeglia, M. Ferrone, 
and S. Pricl, “Synthesis, antifungal and antimycobacterial activities of new bis-
imidazole derivatives, and prediction of their binding to P45014DM by molecular docking 
and MM/PBSA method”, Bioorg. Med. Chem., vol. 15, no. 23, pp. 7444–58, Dec. 2007. 
[153] D. Olender, J. Zwawiak, V. Lukianchuk, R. Lesyk, A. Kropacz, A. Fojutowski, and L. 
Zaprutko, “Synthesis of some N-substituted nitroimidazole derivatives as potential 
antioxidant and antifungal agents”, Eur. J. Med. Chem., vol. 44, no. 2, pp. 645–52, 
Feb. 2009. 
[154] A. Puratchikody and M. Doble, “Antinociceptive and antiinflammatory activities and 
QSAR studies on 2-substituted-4,5-diphenyl-1H-imidazoles”, Bioorg. Med. Chem., vol. 
15, no. 2, pp. 1083–90, Jan. 2007. 
[155] J. T. Leonard, O. S. Rajesh, L. Jeyaseeli, K. Murugesh, R. Sivakumar, and V. G. 
Gunasekaran, “Synthesis, Anti-inflammatory and Antibacterial Activities of Substituted 
Phenyl Benzimidazoles”, Asian J. Chem., vol. 19, no. 1, pp. 116–120, 2007. 
[156] R. V. Devivar, E. Kawashima, G. R. Revankar, J. M. Breitenbach, E. D. Kreske, J. C. 
Drach, and L. B. Townsend, “Benzimidazole Ribonucleosides: Design, Synthesis, and 
Antiviral Activity of Certain 2-(Alkylthio)- and 2-(Benzylthio)-5,6-dichloro-1-(β-D-
ribofuranosyl)benzimidazoles”, J. Med. Chem., vol. 37, no. 18, pp. 2942–2949, Sep. 
1994. 
[157] A. Gellis, H. Kovacic, N. Boufatah, and P. Vanelle, “Synthesis and cytotoxicity 
evaluation of some benzimidazole-4,7-diones as bioreductive anticancer agents”, Eur. 
J. Med. Chem., vol. 43, no. 9, pp. 1858–64, Sep. 2008. 
[158] Y. A. Al-Soud, H. Al-Sa’doni, H. A. S. Amajaour, and N. A. Al-Masoudib, 
“Nitroimidazoles, Part 3. Synthesis and anti-HIV Activity of New N-Alkyl-4-
nitroimidazoles Bearing Benzothiazole and Benzoxazole Backbones”, Zeitschrift für 

85 
Naturforsch. B, vol. 62, no. 4, pp. 523–528, Jan. 2007. 
[159] R. S. Keri, M. R. Patil, S. A. Patil, and S. Budagumpi, “A comprehensive review in 
current developments of benzothiazole-based molecules in medicinal chemistry”, Eur. 
J. Med. Chem., vol. 89, pp. 207–51, Jan. 2015. 
[160] E. Vicente, S. Pérez-Silanes, L. M. Lima, S. Ancizu, A. Burguete, B. Solano, R. Villar, 
I. Aldana, and A. Monge, “Selective activity against Mycobacterium tuberculosis of 
new quinoxaline 1,4-di-N-oxides”, Bioorg. Med. Chem., vol. 17, no. 1, pp. 385–9, Jan. 
2009. 
[161] V. Delgado, A. Ibacache, C. Theoduloz, and J. A. Valderrama, “Synthesis and in vitro 
cytotoxic evaluation of aminoquinones structurally related to marine 
isoquinolinequinones”, Molecules, vol. 17, no. 6, pp. 7042–56, Jan. 2012. 
[162] M. Suffness and J. M. Pezzuto, “Assays related to cancer drug discovery”, in Methods 
in Plant Biochemistry: Assays for Bioactivity, K. Hostettmann, Ed. London: Academic 
Press, 1990, pp. 71–133. 
[163] A. H. Daranas, J. J. Fernández, E. Q. Morales, M. Norte, and J. A. Gavín, “Self-
association of okadaic acid upon complexation with potassium ion”, J. Med. Chem., 
vol. 47, no. 1, pp. 10–3, Jan. 2004. 
[164] A. H. Daranas, P. G. Cruz, A. H. Creus, M. Norte, and J. J. Fernández, “Self-assembly 
of okadaic acid as a pathway to the cell”, Org. Lett., vol. 9, no. 21, pp. 4191–4, Oct. 
2007. 
[165] M. L. Candenas, M. Norte, R. González, E. Arteche, J. J. Fernández, R. Borges, J. 
Boada, C. Advenier, and J. D. Martín, “Inhibitory and contractile effects of okadaic acid 
on rat uterine muscle”, Eur. J. Pharmacol., vol. 219, no. 3, pp. 473–6, Sep. 1992. 
[166] C. J. Pedersen, “Cyclic polyethers and their complexes with metal salts”, J. Am. 
Chem. Soc., vol. 89, no. 10, pp. 2495–2496, May 1967. 
[167] M. Kralj, L. Tusek-Bozić, and L. Frkanec, “Biomedical potentials of crown ethers: 
prospective antitumor agents”, ChemMedChem, vol. 3, no. 10, pp. 1478–92, Oct. 
2008. 
[168] K. Brandt, R. Kruszynski, T. J. Bartczak, and I. Porwolik-Czomperlik, “AIDS-related 
lymphoma screen results and molecular structure determination of a new crown ether 
bearing aziridinylcyclophosphazene, potentially capable of ion-regulated DNA 
cleavage action”, Inorganica Chim. Acta, vol. 322, no. 1–2, pp. 138–144, Oct. 2001. 
[169] S. Liu, “Ether and crown ether-containing cationic 99mTc complexes useful as 
radiopharmaceuticals for heart imaging”, Dalton Trans., no. 12, pp. 1183–93, Mar. 

86 
2007. 
[170] F. K. Schweighardt and J. A. Rubertone, “Perfluoro-crown ethers in fluorine magnetic 
resonance imaging”, EP0307863 (B1)1991. 
[171] W. M. Leevy, G. M. Donato, R. Ferdani, W. E. Goldman, P. H. Schlesinger, and G. W. 
Gokel, “Synthetic hydraphile channels of appropriate length kill Escherichia coli”, J. 
Am. Chem. Soc., vol. 124, no. 31, pp. 9022–3, Aug. 2002. 
[172] F. Supek, T. Š. Ramljak, M. Marjanović, M. Buljubašić, G. Kragol, N. Ilić, T. Smuc, D. 
Zahradka, K. Mlinarić-Majerski, and M. Kralj, “Could LogP be a principal determinant 
of biological activity in 18-crown-6 ethers? Synthesis of biologically active 
adamantane-substituted diaza-crowns”, Eur. J. Med. Chem., vol. 46, no. 8, pp. 3444–
54, Aug. 2011. 
[173] M. Coll, C. Piroddi, J. Steenbeek, K. Kaschner, F. Ben Rais Lasram, J. Aguzzi, E. 
Ballesteros, C. N. Bianchi, J. Corbera, T. Dailianis, R. Danovaro, M. Estrada, C. 
Froglia, B. S. Galil, J. M. Gasol, R. Gertwagen, J. Gil, F. Guilhaumon, K. Kesner-
Reyes, M.-S. Kitsos, A. Koukouras, N. Lampadariou, E. Laxamana, C. M. López-Fé de 
la Cuadra, H. K. Lotze, D. Martin, D. Mouillot, D. Oro, S. Raicevich, J. Rius-Barile, J. I. 
Saiz-Salinas, C. San Vicente, S. Somot, J. Templado, X. Turon, D. Vafidis, R. 
Villanueva, and E. Voultsiadou, “The biodiversity of the Mediterranean Sea: estimates, 
patterns, and threats”, PLoS One, vol. 5, no. 8, p. e11842, Jan. 2010. 
[174] S. K. Prestegard, L. Oftedal, R. T. Coyne, G. Nygaard, K. H. Skjaerven, G. Knutsen, 
S. O. Døskeland, and L. Herfindal, “Marine benthic diatoms contain compounds able 
to induce leukemia cell death and modulate blood platelet activity”, Mar. Drugs, vol. 7, 
no. 4, pp. 605–23, Jan. 2009. 
[175] A. H. Abou Zeid, E. A. Aboutabl, A. A. Sleem, and H. M. El-Rafie, “Water soluble 
polysaccharides extracted from Pterocladia capillacea and Dictyopteris membranacea 
and their biological activities”, Carbohydr. Polym., vol. 113, pp. 62–6, Nov. 2014. 
[176] N. A. Ribeiro, T. M. Abreu, H. V. Chaves, M. M. Bezerra, H. S. A. Monteiro, R. J. B. 
Jorge, and N. M. B. Benevides, “Sulfated polysaccharides isolated from the green 
seaweed Caulerpa racemosa plays antinociceptive and anti-inflammatory activities in 
a way dependent on HO-1 pathway activation”, Inflamm. Res., vol. 63, no. 7, pp. 569–
80, Jul. 2014. 
[177] E. Hao, J. Fromont, D. Jardine, and P. Karuso, “Natural Products From Sponges of 
the Genus Agelas ‒ on the Trail of a [2+2]-Photoaddition Enzyme”, Molecules, vol. 6, 
no. 2, pp. 130–141, Jan. 2001. 
[178] Y. Hu, J. Chen, G. Hu, J. Yu, X. Zhu, Y. Lin, S. Chen, and J. Yuan, “Statistical 

87 
research on the bioactivity of new marine natural products discovered during the 28 
years from 1985 to 2012”, Mar. Drugs, vol. 13, no. 1, pp. 202–21, Jan. 2015. 
[179] T. Rocha-Santos and A. C. Duarte, “Chapter 1 – Introduction to the Analysis of 
Bioactive Compounds in Marine Samples”, in Analysis of Marine Samples in Search of 
Bioactive Compounds, Comprehens., vol. 65, T. Rocha-Santos and A. C. Duarte, Eds. 
Elsevier, 2014, pp. 1–13. 
[180] B. K. Sagitova, “Watching clinical trials liability”, Allianz Global Corporate & Specialty, 
2009. [Online]. Available: http://www.agcs.allianz.com/insights/expert-risk-
articles/watching-clinical-trials-liability/. [Accessed: 01-Oct-2015]. 
 

Screening of Marine Natural Products and Their 
Synthetic Derivatives for Antimicrobial and 
Antiproliferative Properties
CENTRE FOR DRUG RESEARCH
DIVISION OF PHARMACEUTICAL BIOSCIENCES
FACULTY OF PHARMACY
DOCTORAL PROGRAMME IN DRUG RESEARCH
UNIVERSITY OF HELSINKI
SOFIA MONTALVÃO
dissertationes scholae doctoralis ad sanitatem investigandam 
universitatis helsinkiensis 16/2016
16/2016
Helsinki 2016                             ISSN 2342-3161           ISBN 978-951-51-1939-1 
S
O
F
IA
 M
O
N
T
A
L
V
Ã
O
  S
creen
in
g of M
arin
e N
atu
ral P
rod
u
cts an
d
 T
h
eir S
yn
th
etic D
erivatives for A
n
tim
icrobial an
d
 A
n
tip
roliferative P
rop
erties
Recent Publications in this Series
103/2015 Elina Reponen
Preoperative Risk-Assessment Methods, Short-Term Outcome, and 
Patient Satisfaction in Elective Cranial Neurosurgery
104/2015 Riina Kandolin
Cardiac Sarcoidosis in Giant Cell Myocarditis in Finland
106/2015 Karmen Kapp
Polyphenolic and Essential Oil Composition of Mentha and Their Antimicrobial Effect
107/2015 Dina Popova
Neurophysiological mechanisms of Plasticity Induced in Adult Brain
1/2016 Pauliina Saurus
Regulation of Podocyte Apoptosis in Diabetic Kidney Disease  –  Role of SHIP2, PDK1 and CDK2
2/2016 Sanna Toivonen
Derivation of Hepatocyte Like Cells from Human Pluripotent Stem Cells
3/2016 Marjaana Peltola
AMIGO-Kv2.1 Potassium Channel Complex: Identification and Association with Schizophrenia-
Related Phenotypes
4/2016 Niko-Petteri Nykänen
Cellular Physiology and Cell-to-Cell Propagation of Tau in Neurodegeneration: The Impact of 
Late-Onset Alzheimer’s Disease Susceptibility Genes
5/2016 Liisa Korkalo
Hidden Hunger in Adolescent Mozambican Girls: Dietary Assessment, Micronutrient Status, 
and Associations between Dietary Diversity and Selected Biomarkers
6/2016 Teija Ojala
Lactobacillus crispatus and Propionibacterium freudenreichii: A Genomic and Transcriptomic 
View
7/2016 César Araujo
Prostatic Acid Phosphatase as a Regulator of Endo/Exocytosis and Lysosomal Degradation
8/2016 Jens Verbeeren
Regulation of the Minor Spliceosome through Alternative Splicing and Nuclear Retention of the 
U11/U12-65K mRNA
9/2016 Xiang Zhao 
HMGB1 (Amphoterin) and AMIGO1 in Brain Development
10/2016 Tarja Pääkkönen (Jokinen)
Benign Familial Juvenile Epilepsy in Lagotto Romagnolo Dogs
11/2016 Nora Hiivala
Patient Safety Incidents, Their Contributing and Mitigating Factors in Dentistry
12/2016 Juho Heinonen
Intravenous Lipid Emulsion for Treatment of Local Anaesthetic and Tricyclic Antidepressant 
Toxicity
13/2016 Riikka Jokinen
Genetic Studies of Tissue-Specific Mitochondrial DNA Segregation in 
Mammals
14/2016 Sanna Mäkelä
Activation of Innate Immune Responses by Toll-like Receptors and 
Influenza Viruses
15/2016 Mari Hirvinen
Immunological Boosting and Personalization of Oncolytic Virotherapies 
for Cancer Treatment
